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Introduction 
Cigarette smoking is associated with lung cancer, cardiovascular disease, and chronic 
respiratory conditions. It is responsible for high mortality and morbidity risk in the US 
population. Smokers find sudden quitting difficult and it is reported that a large number of 
unassisted quitting attempts are eventually unsuccessful. Electronic cigarette or e-cig is a 
novel battery-driven, nicotine delivery product, currently being used as a smoking 
cessation tool by current and former smokers. Since its resemblance to a conventional 
cigarette, and its non-combustible nature, e-cig use has risen exponentially in the last few 
years. To address such public health issues, the US FDA is working on formulating 
regulations to manufacture, market, and distribute e-cigs has called for research evidence 
on the long term use of e-cig use.  
Objective 
The objective of this study was to develop and validate a Discrete Event Simulation model 
to simulate the electronic cigarette (e-cig) use behavior, and to estimate the long term e-cig 
use prevalence, in different groups of the US population.  
Methods 
The model population was generated from analyzing the National Health Interview Survey 
data from 2011-2013. The population was categorized into current, recent former, late 
former and never smokers. Population birth rates and death rates were applied using the 
2012 US Census Bureau data. Model parametrization, transition probabilities and e-cig 
related risks were obtained and applied using cross sectional survey and longitudinal e-cig 
studies done on US population. The model was run for the period of 15 years and e-cig use 
prevalence at the end of the simulation period was estimated. Each simulation was 
replicated 100 times using Monte Carlo simulation approach. Model validation was 
performed by the use of null and extreme input values (internal validation), examining 
programing codes (debugging), verification by tobacco science and system analysis experts 
(structural and technical validation), comparison of model’s first year results with CDC 
reports (external validation). 
 
 
 
Conclusion 
Total projected e-cig prevalence in the US population at the end of simulation of period was 
found to be around 19%. The results showed a gradual reduction in the number of 
conventional cigarette smokers and an increase in the e-cig users over the simulation 
period. Highest e-cig users were <21 years old, male, white and had less than high school 
level education. Sensitivity analyses of various model parameters showed that the e-cig 
prevalence was most sensitive to the impact and timing of policy implementation.  
As a novel nicotine delivery system, e-cigs are rapidly gaining acceptance in the US and 
recent reports have shown an exponential rise in the popularity of e-cig among minors and 
young adults. Our research provides empirical evidence that can be used by the scientific 
community and regulatory bodies to formulate regulations for marketing and sales of e-
cigs in various sections of the population, where the prevalence is expected to rise in 
future. Our study can also guide the policy makers to introduce relevant policies at specific 
time points when the e-cig use is expected to rise.
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Chapter 1  
Introduction 
 
 
 
 
 
 
 
 
 Background 
 
Cigarette smoking is an important and preventable cause of morbidity in the US associated 
with lung cancer, cardiovascular disease, and chronic respiratory conditions. Recent US 
health care reports (How tobacco smoke causes disease.2010; Health consequence of 
smoking: US surgeon general report.2014) have shown that smokers are at greater risk than 
non-smokers for diseases that affect the heart and blood vessels (cardiovascular disease), 
eventually leading to stroke and coronary heart disease. Further, smoking can cause lung 
diseases by damaging the airways and the small air sacs (alveoli) found in the lungs. This 
leads to COPD, which includes emphysema and chronic bronchitis (Health consequence of 
smoking: US surgeon general report.2014). Cigarette smoking also causes most cases of lung 
cancer in the country (How tobacco smoke causes disease.2010; Health consequence of 
smoking: US surgeon general report.2014). In terms of mortality, the US Centers for Disease 
Control and Prevention (CDC) reports that approximately 443,000 deaths occur annually in 
the US due to smoking, including those from secondhand smoke (Agaku, King, Husten, & 
Bunnell, 2014).  
Along with negative health effects, smoking also results in a high economic burden. Annual 
smoking-attributable economic costs in the United States estimated for the years 2009–
2012 were more than $289 billion, which included approximately $133 billion for direct 
medical care of adults and more than $156 billion for indirect costs due to lost productivity 
(Health consequence of smoking: US surgeon general report.2014). 
Although cigarette smoking is declining among U.S. adults over the past five decades, there 
is still a high proportion of population smoking cigarettes and other tobacco products 
(Agaku et al., 2014). During 2012–2013, the US surgeon general report identified 
approximately one in five U.S. adults (total of 50 million persons) used any tobacco product 
every day or some days, and an estimated 60 million people used tobacco products every 
day, some days, or rarely (How tobacco smoke causes disease.2010; Health consequence of 
smoking: US surgeon general report.2014) . The majority of the smoking population 
consisted of young adults and teenagers. A report from the Center of disease control and 
prevention (CDC) indicated that the prevalence of current tobacco product use among 
middle and high school students was 6.7% and 23.3%, respectively (CDC morbidity and 
mortality report.2013).                                                                        
Offering help to quitting tobacco use in people addicted to nicotine is one of the most 
important policies identified by the World Health Organization (WHO) Framework 
Convention on Tobacco Control (FCTC) to expand the fight against the tobacco epidemic 
(WHO.2012). However, due to the addictive nature of nicotine, most of the smokers are bio-
behaviorally addicted. That is, not only they are dependent on the biological constituents of 
tobacco, but are also dependent on the behavior aspect of using tobacco products like 
holding and puffing on cigarettes.  
Quitting smoking can be very difficult and is often accompanied by variety of withdrawal 
symptoms (Benowitz, 1991). Approximately, 70% of smokers try to quit, but less than 5% 
of unassisted attempts are successful (Benowitz, 1991). Sudden quitting may also result in 
fatigue, dizziness, nicotine withdrawal, irritability, anger, frustration, sad mood, anxiety, 
decreased concentration, hunger, insomnia, restlessness, decreased heart rate, weight gain 
and an eventual relapse of smoking (Benowitz, 1991; Siegel, Tanwar, & Wood, 2011). Many 
smokers intending to quit take help of pharmacotherapy as well as patient counselling but 
smokers using these approaches have shown a high rate of an eventual relapse (Bell & 
Keane, 2012).  
The latest addition to the existing tools for smoking cessation and abstinence is electronic 
cigarettes (e-cigs). Launched in China in 2003, e-cigs are hand-held battery-powered 
nicotine delivery devices which enable users to inhale doses of vaporized nicotine 
(Barbeau, Burda, & Siegel, 2013). A basic model of an e-cig consist of a mouthpiece 
comprising of a liquid-filled cartridge mainly filled with variable concentration of nicotine, 
concentrated flavors, and a humectant substance such as  propylene glycol, vegetable 
glycerin or polyethylene glycol (Besaratinia & Tommasi, 2014). An atomizer equipped with 
an electronic controller, sensor, and battery powered heater converts the liquid inside the 
cartridge into vapor that mimics the cigarette smoke, with a colored LED simulating a 
burning cigarette tip. Used e-cig cartridges can be replaced or refilled with a new cartridge, 
which is readily available in any e-cig store (Besaratinia & Tommasi, 2014). Since no 
tobacco is burned, inhaling nicotine via e-cigs provides a potentially safer alternative to 
smoking regular cigarette since it eliminates the harmful tars and carbon monoxide 
(Dawkins, Turner, Hasna, & Soar, 2012). E-cigs therefore are often perceived to help in 
cigarette smoking cessation and reduction (Dawkins et al., 2012). It also reduces the 
problems of second hand and third hand smoke. (Barbeau et al., 2013; Siegel et al., 2011; 
Zhu et al., 2013).  
Rise in the use of e-cigs and related effects 
 
As a novel nicotine delivery system, e-cig are rapidly gaining acceptance in the US and 
many parts of the world. Currently, the global e-cig market is worth $6 billion and in the US 
alone, the estimated e-cig retail sales approached $2 billion at the end of 2013, and is 
estimated to rise to $10 billion by 2017 (Herzog, 2013). It is anticipated that e-cig sales will 
surpass that of conventional tobacco cigarettes by 2023 (Herzog, 2013). According to a 
study by the Centers for Disease Control and Prevention (CDC), nearly 6% of all U.S. adults 
have used e-cig, and approximately 21% of American adult smokers (i.e., an estimated 
population of 45 millions) have tried e-cig in the past (CDC morbidity and mortality 
report.2013). The Tobacco Vapor Electronic Cigarette Association claims that around 4 
million Americans are e-cig users (TVECA, 2013). This increasing trend for e-cig use also 
extends to minors as the number of U.S. middle and high school students who tried e-cig 
more than doubled between 2011 and 2012, rising from 4.7% to 10% (CDC morbidity and 
mortality report.2013). In 2012, around 1.78 million middle and high school students 
nationwide admitted to using e-cig. Along with that, 76.3% of youth who used e-cig within 
the past 30 days also smoked regular tobacco cigarettes in the same period, giving rise to 
dual use (CDC morbidity and mortality report.2013).  
Although e-cigs has been portrayed as a less harmful substitute for smokers who are 
unable to quit, the counter-argument to the use of e-cig is that it may cause nicotine 
dependence in smokers and long term use may cause health complications (Dutra & Glantz, 
2014; Tomar, 2007). Despite the fact that the e-cigs deliver fewer amounts of nicotine 
vapors than tobacco cigarettes, they nevertheless have showed long term nicotine 
dependency in e-cig users (Tomar, 2007). Also, recent studies done on chemical analysis of 
e-cig vapor/liquid has shown the presence of toxins and carcinogens, generally at lower 
levels, in various e-cig products (Goniewicz, Kuma, Gawron, Knysak, & Kosmider, 2013; 
Kim & Shin, 2013; McAuley, Hopke, Zhao, & Babaian, 2012).  
 
The rising popularity of e-cig among minors and young adults is particularly concerning 
because these products may serve as a ‘gateway’ to using conventional tobacco products. In 
other words, e-cigs use has potential unintended consequences, such as becoming “starter 
products” for non-smokers, especially young adults, leading to increased smoking initiation 
and derailing the potential for ultimate smoking abstinence (Pepper et al., 2013; Riker, Lee, 
Darville, & Hahn, 2012). Because the vast majority of smokers pick up the habit as 
teenagers (Pearson, Richardson, Niaura, Vallone, & Abrams, 2012), the excessive use of e-
cig by teenagers and young adults is a critical concern because it may ultimately lead to 
long lasting smoking habits.  
The use of e-cig also draws attention to the increasing trend of dual use claiming that 
smokers may use e-cig to temporarily alleviate their craving for tobacco cigarettes, 
especially in settings where smoking is prohibited. Under such assumption, dual users may 
take advantage of e-cig as a ‘quick fix’, and maintain their smoking status without feeling 
the need to quit smoking (Pepper et al., 2013). 
 
 
 
Regulatory Perspective to the use of e-cig 
 
The WHO stated that the efficacy of e-cig in aiding smoking cessation had not been 
demonstrated scientifically, and recommended that consumers should be advised not to 
use e-cig until the recognized regulatory bodies have found them safe and effective 
(WHO.2012). Since then, several countries such as Australia and Canada have restricted the 
sale of e-cigs until pending review by their regulatory agencies (WHO.2012). At present, the 
FDA is formulating regulations for the sale and marketing of e-cig as a smoking cessation 
product. However, the nature of the regulation procedure is yet to be determined as there 
is a lack of research evidence on the health impact of using e-cigs (WHO.2012; Henningfield 
& Zaatari, 2010).  
In the US, with the enactment of the Family Smoking Prevention and Tobacco Control Act 
(FSPTCA) in 2009, the FDA was granted authority to regulate the manufacture, marketing, 
and distribution of tobacco products to protect the public health and to reduce tobacco use 
by minors (Family smoking prevention and tobacco control act (FSPTCA).2014). Within the 
framework of the FSPTCA, the FDA and the National Institutes of Health (NIH) have formed 
an interagency partnership to foster research relevant to tobacco regulatory science, and 
identified multiple research opportunities, including e-cig initiation, use (including 
transition to other tobacco products and multiple use), perceptions, dependence, and 
toxicity (Tobacco regulatory science program (TRSP).2014). 
 
The ongoing and future research on these topics is expected to provide empirical evidence 
that can be used to inform the general public, scientific community, and regulatory 
authorities of the health risks and benefits associated with e-cig use. Not only will this 
information help generate further interests for scientists in the field of tobacco regulatory 
research, but it will also assist the regulatory agencies in making scientifically based 
decisions on the development and evaluation of regulations on novel tobacco products 
such as e-cigs to ensure safety of public health.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Chapter 2 
 
Literature Review 
 
 
 
 
 
 
 
 
 
 
 
 
Tobacco use is a global phenomenon, affecting an estimated 1.2 billion people, which poses 
substantial health burden and costs. With approximately 5 million tobacco-related deaths 
annually, cigarette smoking is the leading cause of preventable premature mortality in the 
world (World health organization.1997). The risk of serious disease diminishes rapidly 
after quitting and permanent abstinence is known to reduce the risk of lung cancer, heart 
disease, chronic lung disease, stroke, and stroke (Health consequence of smoking: US 
surgeon general report.2014; Lightwood & Glantz, 1997). 
Existing treatments for smoking cessation includes various methods, from simple medical 
advice to pharmacotherapy. However, the potential addictive nature of nicotine creates a 
huge obstacle for those who desire to quit smoking. It has been shown that approximately 
80% of smokers who attempt to quit on their own relapse within the first month of 
abstinence and only about 3-5% remain abstinent at 6 months (Hughes, Keely, & Naud, 
2004).  
 
Smokers often take help of drug therapies to help them quit their smoking habit. The latest 
treating tobacco use and dependency guidelines of US Department of Health and Human 
Services (How tobacco smoke causes disease.2010)categorizes pharmacotherapy for 
treatment of tobacco dependence into first-line (nicotine replacement therapy [NRT], 
bupropion, and varenicline) and second-line medications (include nortriptyline and 
clonidine). Most of the first line medications have established efficacy profiles but the FDA 
has not approved the second line medications for tobacco dependence treatment indication 
and there are concerns about their potential side effects (Hays, Ebbert, & Sood, 2009a).  
NRT is the most common existing medication used to assist tobacco cessation. It acts by 
partially replacing the nicotine formerly obtained from tobacco smoking and aids smoking 
cessation by weakening the reinforcing effects of nicotine delivered via tobacco, and 
therefore reducing the severity of withdrawal symptoms and cravings (Gross & Stitzer, 
1989). Despite the first line treatment, NRT does not completely eliminate all symptoms of 
withdrawal because the delivery system does not reproduce the rapid and high levels of 
nicotine achieved through regular tobacco use. (Benowitz, 1991). Differences in 
formulations (lozenge, gum, patch, nasal spray, and inhaler) may provide some relief to the 
withdrawal symptoms or urges to smoke, but there is little direct evidence that one 
nicotine product is more effective than another (Benowitz, 1991). In general, NRT is 
considered to be safe for most patients, with a relatively low rate of discontinuation due to 
adverse events (Tonnesen & Mikkelsen, 2000).  
 
Bupropion hydrochloride (brand names: Zyban, Wellbutrin), another first line smoking 
cessation drug is found to be effective as a smoking-cessation aid, with sustained-release 
(SR) oral formulations as well as immediate release. The mode of action of bupropion in 
smoking cessation is not clearly explained but inhibition of neuronal reuptake of dopamine 
and a weak nAChR antagonist effect are thought to contribute to the reported reduction in 
the severity of nicotine cravings and withdrawal symptoms (Jorenby, 2002). Pooled 
analyses of studies with bupropion generally show quit-rates similar to those observed 
with NRT (Hughes, Stead, Hartmann-Boyce, Cahill, & Lancaster, 2014). However, bupropion 
have been commonly associated with insomnia and dry mouth (Hughes et al., 2014).  
 
Varenicline (brand names: Chantix/Champix1), launched in 2006, became the first new 
prescription drug for smoking cessation in 10 years. Varenicline acts by dual effects: partial 
stimulation of nAChRs, without creating the full effect of nicotine (agonist action), and 
blocking nAChRs, which prevents the nicotine from tobacco from reaching them 
(antagonist action) (Tonstad et al., 2006). These effects provide relief from the cravings 
and withdrawal symptoms experienced during smoking cessation (Tonstad et al., 2006).  
Varenicline is generally well tolerated, however it is still associated with adverse effects 
including nausea, insomnia, gastrointestinal upsets and headache (Hughes et al., 2014). The 
prescribing information for varenicline also carries a black-box warning highlighting an 
increased risk of psychiatric symptoms and suicidal ideation in patients reporting any 
history of psychiatric illness (Tonstad et al., 2006). 
 
Both nortryptiline and clonidine are second-line medications for treatment of tobacco 
dependence but they do not have approval from the US FDA for this indication, as there are 
concerns about potential side effects (Fiore, 2000).  Combinations of smoking-cessation 
medications such as nicotine patch plus a more rapid release NRT such as gum, lozenge or 
spray, or bupropion plus NRT, have shown to increase efficacy in smoking cessation 
compared to monotherapy (Fiore, 2000).  
 
The use of e-cigs, also referred to as vaping, is a relatively new phenomenon that is rapidly 
gaining the interest of many long-time tobacco users and health care professionals. E-cigs 
are becoming a preferred alternative for nicotine delivery among many smokers because of 
their realistic look, feel, and taste compared to traditional cigarettes. Furthermore, many 
cigarette smokers have turned to vaping because e-cigs vendors are marketing their 
product as a cheaper and safer smokeless alternative to traditional cigarettes, and a 
possible smoking cessation tool (Herzog, 2013).  Awareness and vaping of e-cigs has 
increased exponentially in recent years. Data obtained from surveys and smoking reports 
showed that in the US, awareness of e-cigs rose from 40.9–57.9% from 2010 to 2011, with 
e-cigs use rising from 3.3–6.2% over the same time period [King et al. 2013].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Conceptual framework 
 
The substitution of conventional tobacco products by newer e-cigs draws similarity from 
effective patient behavior changes, which are required to help maintain and improve 
health, reduce disease risks, and control illnesses. Most of the successful health programs 
and interventions are based on an understanding of patient’s health behaviors with respect 
to different contexts. Several different approaches or interventions are currently observed 
to be practiced by health care providers to modify patient behavior. The most commonly 
targeted behaviors are tobacco use, diet and physical activity patterns, alcohol 
consumption, medication adherence, unsafe sexual behavior, and preventive behavior such 
as screening and vaccinations (Ashenden, Silagy, & Weller, 1997; Grol & Grimshaw, 2003). 
 
Literature shows it is highly difficult for patients to completely quit a long-term habit at 
once, such as smoking or alcoholism (Hays, Ebbert, & Sood, 2009b). It is observed that 
counseling patients to completely stop smoking or consuming alcohol does not deter 
patients’ habits and results in withdrawal symptoms and other stressful conditions. 
Clinicians and therapists are observed to offer alternative pharmacotherapies (nicotine 
replacement therapy), substitute but less harmful products or group and individual 
counseling to patients wanting to quit. It is a proven fact that offering these alternatives 
and less harmful products (substitute products) ends up being more successful in reaching 
eventual abstinence than asking them to completely quit their habit (Ashenden et al., 
1997). Along with offering substitute products, exposing patients to threats and benefits of 
a particular behavior also helps to achieve a health related action (Grol & Grimshaw, 2003).  
In context of the behavior of tobacco use or cigarette smoking, it is an addiction that is 
difficult to break. Smokers trying to quit have to cope simultaneously with the 
psychological and pharmacologic aspects of tobacco dependence (Polosa & Benowitz, 
2011). Along with the pharmacological effects of nicotine which results in symptoms like 
nausea, insomnia, fatigue, restlessness and increased cardiovascular rhythm, it is crucial to 
note the importance of behavioral aspects of tobacco dependence. The rising popularity of 
e-cigs can be attributed to their ability to deal with both the pharmacological (i.e. nicotine) 
and the behavioral component (similar shape, mechanism and pleasure) of smoking 
addiction. Most of the drug therapies do not deal with the behavioral aspects of smoking 
cigarettes. E-cigs, on the other hand, provide simulation of smoking behavior with its 
physical similarity with a conventional cigarette and the feeling of inhaling and exhaling 
smoke, which are important determinants of its effectiveness in reducing or substituting 
cigarette smoking. 
Along with pacifying the withdrawal symptoms of nicotine, the action of using an e-cig is 
also perceived to protect the smokers from getting smoking-related diseases and overcome 
other negative effects such as social unacceptability among family and friends. The 
potential benefit of an e-cig in addition to lower barriers associated with the use of e-cigs 
which include experiencing the same pleasure as tobacco cigarette, habitual of inhaling 
smoke, price-difference between e-cig and regular cigarette, and handling and carrying 
issues results in high acceptability of e-cigs among the youth and adult smoking population.  
The high awareness of e-cig via media advertising, observing other people using it and easy 
accessibility and availability of e-cig also contributes to its successful initiation among 
different sections of the population.  
 
Impact on public health 
 
Despite the fact that the e-cigs deliver fewer amounts of nicotine vapors than tobacco 
cigarettes, they nevertheless have showed long term dependency in e-cig users (Tomar, 
2007). To counter this, the proponents of e-cigs claim that use of e-cigs is safer because 
tobacco is not combusted and there is no inhalation of the toxins found in cigarette smoke 
(Barbeau et al., 2013). However, the FDA has reported that e-cig cartridges and solutions 
contain nitrosamines, di-ethylene glycol, and other contaminants potentially harmful to 
humans (Westenberger, 2009). Based on this, the FDA wants the sale of e-cigs to be 
prohibited or regulated as dangerous nicotine delivery systems that should comply with 
the safety standards of the Federal Food Drug and Cosmetic Act (FDCA.2013). 
Studies conducted by Foulds et al. (Foulds, Veldheer, & Berg, 2011) believe that more 
research needs to be conducted to determine the safety and efficacy of e-cigs as a smoking 
cessation tool. However, they also stated that individuals who have successfully quit 
smoking in favor of vaping should continue to use e-cigs as a healthier alternative to 
conventional cigarettes. E-cigs could play an important role in the future of smoking 
cessation, but their use is currently under scrutiny by a complicated legal and political 
issues. It is evident that there is a need to conduct more research on the long-term effect 
and net benefits of e-cigs, to be able to formulate the control measures which will 
streamline the legal and political ramifications surrounding these products.  
The potential health hazards of nicotine addiction from other smokeless tobacco products 
have been previously published by the American Heart Association and include 
hemodynamic effects, endothelial dysfunction, thrombogenesis, systemic inflammation, 
and other metabolic effects (Piano et al., 2010). Because of that, there is a concern that 
increased availability of e-cigs could increase worldwide nicotine dependence, especially 
among the young as they are enticed by the various flavor options e-cigs have to offer. Also, 
since vaping does not produce smoke from burning tobacco, the opponents of e-cigs fear 
that traditional smokers will substitute vaping for smoking in settings where smoking is 
not permitted without any real intention of quitting conventional cigarettes. Furthermore, 
vaping in public places could possibly undermine or weaken current antismoking 
regulations.  
In order to face these challenges, it is very important to become more familiar with the 
available scientific evidence- based literature concerning e-cig and vaping. Currently, the 
literature is limited, but it is growing fast and more studies are getting published in the 
areas of e-cig based surveys studies, chemical analysis of e-cigarette cartridges, nicotine 
content, delivery, and clinical and physiological studies, and evaluating long term effect of 
vaping. We attempt to comprehensively review the literature published till date on 
aforementioned areas and try to address the gap in the current literature. The studies 
discussed are categorized on the basis of their study designs including survey design, 
experimental, cohort and physiological studies.  
Survey studies 
 
The biggest survey study done on e-cig users was done by Adkison et al, to examine the e-
cig related awareness, use, and product-associated beliefs among current and former 
cigarette smokers in the U.S., Canada, Australia, and the UK (Adkison et al., 2013). The 
survey was conducted via telephonic interviews from July 2010 to June 2011and the data 
were analyzed to explore changes in smoking behavior between e-cig users and non-users. 
Results indicated that e-cig awareness ranged from 73% in the U.S. to 20% in Australia. 
Among those aware, 16% had tried e-cigs (7.6% of the total sample), and among those who 
had tried e-cigs, 39% (2.9% of the sample) were current users. Across countries, awareness 
of these relatively new products was higher among younger, non-minority populations 
with higher incomes. Trial and use of e-cigs was associated with smoking status and 
frequency of smoking, with nondaily smokers being the most likely to try e-cigs, although 
there were few non-daily smokers in the sample. Current use was associated with a greater 
reduction in cigarettes per day over time, compared to non-e-cig users (among cohort 
participants, where data were available); however, users were not more likely to quit 
smoking than non-users. 
 
Another four country survey conducted by Etter et al in France, Belgium, Switzerland and 
Canada reported the usage patterns of e-cigs, reasons for use, and users' opinions of these 
products (Etter, 2010). The results of the study suggested that e-cigs were are mainly 
marketed to current smokers either for enjoyment or for use in smoke-free places, and 
most people who bought these products were current and former smokers, who used e-
cigs to help quit smoking, just as they would use NRT. The survey also showed that e-cigs 
were used quite intensively by almost all respondents daily and the number puffs per day 
was substantial. The studied showed that the users reported more positive than negative 
effects with e-cigs and many reported perceived positive effects on the respiratory system 
(breathing better, coughing less), compared to regular cigarette smoking. The study also 
reported that many respondents reported that the e-cigs helped them quit smoking, and 
several compared it favorably with either nicotine patch or bupropion. The respondents 
also reported that e-cigs relieved craving and withdrawal, which was an added benefit over 
nicotine patches. It was also reported that dry mouth and throat was a frequent adverse 
effect of the e-cigs.  
 
A longitudinal survey study done by Etter and Bullen reported the change over time in the 
behavior of e-cig users (Etter & Bullen, 2014). Data were collected at the baseline and after 
12 months. The study reported information on the natural behavior of an international 
cohort of vapers over 12 months outside clinical settings or efficacy trials. The results 
reported that most of the e-cig users were former smokers, who used e-cigs much like 
nicotine medications, to assist quitting, but with a longer duration of use. Among e-cig 
users, a low proportion of former smokers and recent quitters relapsed to smoking. Dual 
users of e-cigs and conventional cigarettes were shown to reduce their cigarette 
consumption after they started to vape, and about half had stopped smoking at 1-year 
follow-up.  
 
Another survey study conducted by Pearson et al, addressed the knowledge gap by using 
cross-sectional data from 2 separate surveys conducted in 2010, exclusively on the US 
population of e-cig users to estimate e-cig awareness, use, and harm perceptions in the 
adult US population (Pearson et al., 2012). The first survey was a nationally representative 
survey (Knowledge Networks’ Knowledge Panel) and the second one was from the follow-
up of a large cohort of current smokers and recent former smokers (Legacy Longitudinal 
Smoker Cohort (LLSC).  The study reported that national estimates of e-cigs ever-use 
prevalence was 11.4% for smokers, 2.0% for former smokers, and 0.8% for never smokers. 
It also reported that roughly 5 million smokers and more than 1 million former and never 
smokers reported to have used e-cigs. Ever use was mostly concentrated among current 
smokers, young adults, and non-Hispanic Whites. It was also indicated that the use was 
popular among those with a college degree. Current e-cig use was most common among 
current smokers (4.1%) and former smokers (0.5%). 
 
A face-to-face survey was conducted by Foulds et al on experienced e-cig users attending a 
meeting for e-cig aficionados (e-cig experts), described the e-cig products they used and 
discussed the public health issues raised by these products and implications for clinicians 
(Foulds et al., 2011). The results of this study were mostly consistent with previous online 
or e-mail based surveys of e-cig users and found out that a high proportion had completely 
replaced cigarette smoking with e-cig use. Among 3000 ever users of e-cigs, 77% used e-
cigs to quit smoking or avoid relapsing and 20% stated that they used e-cigs to reduce 
tobacco consumption with no intention of quitting smoking. Most of the ex-smokers in that 
study (79%) feared that they might relapse to smoking if they stopped using the e-cig. 
 
A more recent 1 year longitudinal e-cig analysis was conducted by Grana et al on a national 
sample of current US smokers to determine whether e-cig use predicted successful quitting 
or reduced cigarette consumption (Grana, Popova, & Ling, 2014). The participants were 
current smokers recruited from the Knowledge Networks probability-based web enabled 
panel who completed baseline (November 2011) and follow-up (November 2012) surveys. 
The study reported that significantly more women, younger adults, and individuals with 
less education used e-cigs. At baseline, a greater proportion of e-cig users reported 
smoking their first cigarette less than 30 minutes after waking compared with non-users. 
Also, baseline e-cig use was not shown to be significantly associated with greater intention 
to quit smoking. E-cig use at baseline did not significantly predict quitting 1 year later. A 
second model including intent, consumption, and dependence covariates found that 
intention to quit and cigarettes smoked per day significantly predicted quit status while 
past 30-day e-cigarette use did not. Among participants who reported smoking at both 
baseline and follow-up, e-cigarette use at baseline was not associated with a change in 
cigarette consumption, controlling for baseline cigarette consumption. 
 
Siegel et al reported the results of a survey conducted using a non-convenience sampling 
frame of all fırst-time purchasers of a particular brand of e-cigs (Siegel et al., 2011). The 
survey was done to determine the effectiveness of e-cigs for smoking cessation. The results 
of this study showed a 6-month point prevalence of smoking abstinence among the current 
e-cig users as 31.0%. Respondents who were not smoking at the 6-month point, or past e-
cig users, around one-third of them were reported as nicotine-free. Around 67% of 
respondents reported a reduction in the number of cigarettes they smoked and around 
49% of respondents reported abstinence from smoking.  
 
Dutra et al used the National Youth Tobacco Survey, which recently started to capture the 
information related to e-cig use among the youth population, to further examine the 
relationship between e-cig use and conventional cigarette smoking and smoking cessation 
among US adolescents (Dutra & Glantz, 2014). The data analysis showed that dual use of e-
cigarettes and conventional cigarettes was high among adolescents and increasing rapidly. 
Adolescents who had ever used a cigarette (not even one puff) and used e-cigs, were more 
likely to report having smoked at least 100 cigarettes and to be current smokers than 
adolescents who never used e-cig. Thus, it showed that the e-cig users were becoming 
heavier smokers and less likely to stop smoking cigarettes. These results cast a serious 
doubt that e-cigs are effective as smoking cessation aids.  
 
Similar to Dutra and his colleagues, Lee et al used a nationalized database in Korea to 
assess the prevalence of e-cig use as well as the relationship between e-cigarette use and 
current cigarette smoking, cigarettes per day, attempts to quit conventional cigarettes, and 
stopping smoking cigarettes (Lee, Grana, & Glantz, 2014). The findings of this study 
reported a high dual use of cigarettes and e-cigs, and that e-cigs were not being used as a 
substitute for cigarettes among Korean adolescents. Around 9.4% of Korean adolescents 
were found to have ever tried e-cigs and 4.7% were current users. Furthermore, a 
significant association between current e-cig use and higher levels of cigarette 
consumption was found, compared to ever and never e-cig user. Tenth graders had the 
highest e-cig use and 12th graders had the highest conventional cigarette use. The study 
also reported that among ever e-cig users, around 85% were dual users. Also, among 
current e-cig users, more than 75% were dual users.  
 
Studying the willingness to use and the gateway effect of e-cigs, Pepper et al conducted a 
study to understand how male adolescents would respond to e-cigs (Pepper et al., 2013). 
The study surveyed a national sample of males ages 11-19 to explore their awareness of e 
cigarettes and their willingness to try them, along with the proportion of population 
showing dual use. The sample population consisted of parents with sons’ ages 11-17 years 
and male adolescents of ages 18-19 years. The results showed that around two thirds were 
aware of e-cigs, out of which older adolescents were more likely to be aware of e cigarettes 
than younger adolescents, while Hispanic adolescents were less likely to be aware 
compared to their non-Hispanic counterparts. The results also showed that nearly 1 in 5 
adolescent males were willing to try either a plain or flavored e cigarette. After controlling 
for significant correlates, the odds of a smoker being willing to try an e cigarette were 10 
times the odds of a nonsmoker.  
 
A large cross-sectional survey of a representative sample of the English population 
conducted by Brown et al used data from an ongoing national surveillance program (the 
Smoking Toolkit Study) which has been tracking the use of e-cigs as a reported aid to 
cessation among the general population in England since July 2009 (Brown, Beard, Kotz, 
Michie, & West, 2014). The study aimed to address the question of how effective e-cig were 
compared with NRT bought over-the-counter and unaided quitting in the general 
population of smokers who were attempting to stop. The primary outcome was self-
reported abstinence up to the time of the survey, adjusted for potential confounders 
including nicotine dependence. The results showed that the in the study population (5863 
smokers), 7.9% had used e-cigarettes, 32.8% had used NRT bought over-the-counter and 
59.3% had used no aid to cessation. Quitting method did not differ by sex or the number of 
quit attempts in the past year but was associated with age, social grade, time since the quit 
attempt started, CPD, smoking less than one CPD, the measures of dependence (time with 
and strength of urges and HSI) and whether the attempt had begun abruptly. Further 
comparisons showed that those who used either e-cigs or no aid were younger than those 
using NRT over-the-counter, and that those who used NRT over-the-counter or no aid were 
more likely to hold a lower social grade than those using e-cigarettes. E-cig users smoked 
more cigarettes, and were more dependent by the strength of urges measure and heaviness 
of smoking index (HIS), than those using no aid.  
 
A more recent study done on e-cig population in Spain by Martinez et al aimed to estimate 
the prevalence and analyze the correlates of current and ever use of e-cigarettes, including 
purchase location and satisfaction with its use, in a sample of the general population of the 
city of Barcelona in 2013 and 2014 (Martinez-Sanchez et al., 2014). The study utilized data 
from a survey of representative sample of the adult (n=1245) and asked questions on 
current use, ever use and experimentation with e-cigs. The results showed that the 
prevalence of ever e-cigarette use was 6.5%, with the population distribution as mean age 
of 45.1 years, 56.2% men and 58.3% with intermediate educational level. In total, 75% of e-
cig users were current cigarette smokers (dual use), 22.9% were former smokers and 2.1% 
were never-smokers at the time of the interview. The prevalence of ever e-cig use was 
higher among men (8%), younger people (≤44 years old, 13.1%) and people with 
intermediate educational level (9.8%). There was a statistically significant association 
between ever e-cigarette use and current smoking (OR=54.57) and the highest prevalence 
(46.4%) of ever e-cig use was among current smokers with a high cigarette dependence 
score. 
 
King et al from the National Center for Chronic Disease Prevention and Health Promotion at 
the CDC analyzed data from the 2010 and 2011 “Health Styles” surveys, a consumer panel 
survey, to determine estimates of the national prevalence and socio-demographic 
correlates of awareness and ever-use of e-cigs among U.S. adults (King, Alam, Promoff, 
Arrazola, & Dube, 2013). The survey results showed that the awareness and use of e-cigs 
were increasing rapidly. Approximately 6 in 10 adults were found to be aware of e-cigs in 
2011 compared with 4 in 10 adults in 2010. Moreover, in 2011, 6.2% of all adults and 
21.2% of current smokers had ever used e-cigs, representing an approximate doubling of 
2010 estimates. Differences in awareness and use of e-cigs were observed across 
subpopulations such as adults <65 years of age, non-Hispanic Whites, and current and 
former smokers were most aware of e-cigs. Current smokers were significantly higher 
users of e-cigs than non-smokers.  
 
Experimental studies 
 
Since the launch of the e-cig, there have been couple of randomized controlled trials 
performed on the e-cig users. The randomized controlled trial conducted by Bullen et al 
from 2011 till 2013 in New Zealand, aimed to assess whether nicotine e-cigs were more 
effective for smoking cessation than nicotine patches, and included a blind comparison 
with e-cigs containing no nicotine (placebo e-cig) (Bullen et al., 2013). The results showed a 
significant reduction of the mean cigarette consumption by two cigarettes per day more in 
the nicotine e-cigs group than the patches group (P = 0.002). It was also observed that 57% 
of the e-cigs group reduced daily cigarettes by at least half at 6 months than in the nicotine 
patches group(41%; P = 0.0002) and in the placebo e-cig group (45%; P = 0.08). The results 
also showed an abstinence at 6 months after quit day of 7.3% in the nicotine e-cig group, of 
5.8% in the nicotine patches group (5.8%), and of 4.1% in the placebo e-cig group. 
Moreover, time to relapse in the nicotine e-cig group was observed to be 35 days, more 
than twice as long as in the patches group (14 days) or placebo e-cigarettes group (12 
days). 
 
The ECLAT trial (Efficiency and safety of an electronic cigarette) was a prospective 12-
month, double-blind, randomized controlled trial conducted by Caponnetto and his 
colleagues in Italy, during the period June 2010– February 2011 (Caponnetto et al., 2013). 
It was designed to assess the efficacy and safety of e-cigs loaded with different strengths of 
nicotine (7.2 mg, 5.4 mg and no nicotine cartridges). The results of this study showed a 
decline in cigarette per day used in all three groups, with no consistent differences among 
study groups. Smoking reduction was reported documented in 22.3% and 10.3% at Weeks 
12 and 52, respectively. Complete abstinence from tobacco smoking was reported as 11%, 
17% and 4% in the three arms respectively, at week 12 and 13%, 9% and 4% in the three 
arms respectively at week 52 (P= 0.001 versus baseline). 
 
In another smaller scale trial in terms of participants, Dawkins et al chose 86 e-cig naive 
smokers and randomly allocated them to either 18 mg nicotine e-cig (nicotine), 0 mg e-cig 
(placebo) or just hold the e-cig (just hold) groups (Dawkins et al., 2012). The study 
reported that desire to smoke declined over time for both nicotine and placebo groups 
relative to the just hold group. After using the e-cig, the mean desire to smoke score 
significantly changed from 4.5 (at baseline) to 2.5, 20 min after use (P=0.05). The difference 
was found to be statistically significant for males and females from baseline to 20 minutes. 
 
Cohort studies 
 
Polosa et al conducted a proof-of-concept study to monitor changes in the smoking habits 
of a group of regular smokers in Italy, focusing on smoking reduction and smoking 
abstinence (Polosa et al., 2011). Eligible participants were followed up prospectively for 6 
months. The study reported that in 13 of the total 40 (32.5%) participants, the use of 
cigarette per day was reduced by 50% at the end of the study (P= 0.001). A reduction of 
80% in the number of cigarettes smoked was observed in 5 of the 40 participants (12.5%, 
P= 0.043). 
 
A similar proof-of-concept study was conducted by Caponnetto et al to monitor 
modifications in the smoking habits of a group of regular smokers with schizophrenia 
experimenting a popular brand of e-cigs (Caponnetto, Auditore, Russo, Cappello, & Polosa, 
2013). The study participants were followed up prospectively for 12 months. The results 
showed a reduction of 50% in the number of cigarette per day in 7 of the14 participants 
and the median value of 30 cigarettes per day decreased significantly to 15 cigarettes per 
day (P =0.018). Additionally, sustained smoking abstinence at week 52 was observed in 2 
of the 14 (14.3%) participants. 
 
Farsalinos et al conducted a study to examine the profile and e-cig use patterns in a specific 
group of past cigarette smokers who managed to completely substitute smoking with e-cig 
use without using any other aid (Farsalinos, Romagna, Tsiapras, Kyrzopoulos, & Voudris, 
2013). The study focused on evaluating nicotine levels used, reported side effects and 
benefits, and the dependency potential of e-cigs compared with tobacco cigarettes. The 
study reported that a significant proportion (42%) of the participants quit smoking during 
the first month of using e-cigs.  Most participants reported increasing the nicotine 
concentration in their e-cigs in order to achieve complete substitution of smoking.  More 
than 80% of e-cig users were reported to quit smoking cigarettes by using nicotine levels 
higher than 15 mg/mL.  
 
Polosa et al investigated long-term efficacy of the e-cigs as a smoking-cessation tool in a 
cohort of current smokers followed up to 24 months (Polosa et al., 2014). The prospective 
observational study evaluated smoking reduction and abstinence by measuring >50 % 
reduction in the number of cig/day from baseline, >80 % reduction in the number of 
cig/day from baseline, and complete abstinence from smoking. The outcomes were 
measured at the baseline, 6 months, 18 months and 24 months. The results showed a 
significant overall 80 % reduction in median cig/day use from 25 to 4 cigarette by the end 
of the study. Sustained 50 % reduction in the number of cig/day at 24 months was seen in 
27.5 % subjects. There were 12.5 % quitters by the end of the study. Overall, combined 
sustained 50 % reduction and smoking abstinence was seen in 40 % participants at 24 
months, with a median of 24.5 cig/day decreasing significantly to 4 cig/day (p<0.001). 
 
Another study conducted by Rigotti et al described the prevalence of current e-cig use 
among adults who were admitted to nine acute-care hospitals in five geographically 
dispersed U.S. cities (Birmingham, AL; Boston, MA; Kansas City, KS; New York, NY; and 
Portland, OR) over 3.5 years, from July 2010 to December 2013 (Rigotti et al., 2014). The 
study evaluated the association between self-report of having used one or more e-cigs in 
the 30 days before the hospital admission and covariates including enrollment date, age, 
sex, race/ethnicity, marital status, educational attainment, health insurance, type of 
admission (emergency room vs. other), number of cigarettes per day before admission, and 
whether the smoker planned to quit smoking after discharge. The results showed that 
overall 14% of all patients (n=4660) admitted between July 2010 and December 2013 
reported having used an e-cig in the 30 days prior to their hospital admission. Out of all the 
covariates, e-cig use significantly varied by the patient characteristics of age, 
race/ethnicity, education and cigarettes smoked per day. The results also showed that the 
prevalence of e-cig use significantly increased over time, from 1.1% in 2010, to 10.3% in 
2011, to 10.2% in 2012, and 18.4% in 2013 (p < .0001). Younger smokers (<45 years), 
heavier smokers (≥10 cigarettes/day), and those with more education (high school diploma 
or more) were more likely to have used an e-cigarette in the 30 days before hospital 
admission, controlling for other factors.  
 
Physiological studies 
 
Vansickel et al conducted a study to characterize e-cig users' nicotine and CO exposure, 
cardiovascular response, and ratings of nicotine abstinence symptom suppression 
(Vansickel, Cobb, Weaver, & Eissenberg, 2010). The study involved 32 tobacco cigarette 
smokers and compared the effect of two e-cig brands with own brand cigarettes and 
placebo smoking (i.e., puffing on an unlit cigarette). The results of this acute study 
suggested that two 10-puff bouts with the e-cigs exposed users to no significantly 
measurable nicotine or CO and did not increase heart rate. The results also showed that 
neither of the e-cig exposed users to measurable levels of nicotine or CO, although both 
suppressed nicotine/tobacco abstinence symptom ratings.  
 
Another study looking at the cardiovascular effects was conducted by Eissenberg et al and 
it examined how two brands of e-cigs influenced plasma nicotine levels, heart rate and 
cigarette craving in cigarette smokers, and compared these effects to those produced by 
smokers’ usual brand of cigarettes (Eissenberg, 2010). The study recruited 16 naive e-cig 
users who used either their own brand cigarettes, sham smoking (puffing an unlit 
cigarette), or two different brands of e-cigs. The results of the study showed that relative to 
tobacco cigarette, 10 puffs from either of the branded e-cigs delivered little to no nicotine 
and suppressed craving less effectively.  
 
Vansickel et al conducted a second study to investigate an initial abuse liability assessment 
of an e-cig brand current regular cigarette smokers (Vansickel, Weaver, & Eissenberg, 
2012). To accomplish this, the nicotine delivery profile, subjective and cardiovascular 
effects of an e-cig were examined following puffs of regular cigarettes and bouts of the e-
cigs. Their plasma nicotine concentration, heart rate and subjective effects were measured. 
It was observed that tobacco abstinence symptom suppression and increased product 
acceptability ratings were associated with e-cig. In terms of heart rate, there was an 
insignificant increase observed from a pre-administration average of 67.5 beats per minute 
to 75 beats per minute, 5 minutes after the first e-cig bout. No effect of e-cig administration 
was observed for systolic or diastolic pressure.  
 
Flouris et al conducted a study to assess the acute impact of active and passive e-cigarette 
smoking on serum cotinine and lung function, as compared to active and passive tobacco 
cigarette smoking (Flouris et al., 2012). Fifteen current and fifteen never-smokers were 
asked to undergo a control session, an active tobacco cigarette smoking session and an 
active e-cig smoking session and their serum cotinine, lung function, exhaled carbon 
monoxide(CO)and nitric oxide were assessed at the baseline, immediately post and 1 hour 
post exposure of the sessions. The results showed a statistically significant linear 
association between the serum cotinine levels observed immediately after and 1 hour after 
the active tobacco and active e-cig sessions. Further, no statistical difference in the lung 
function data was observed within each individual time point (i.e. baseline, immediately 
post and 1 h post-exposure), in both groups. In the active control group, no significant 
fluctuations were observed in the lung function and serum cotinine concentration. In 
contrast, the lung function and CO levels changed significantly across time during the active 
tobacco session. During the active e-cog session, cotinine was found to be fluctuated 
significantly but no significant effect was observed in lung function and exhaled CO.  
 
Another study to assess the physiological impact of e-cig was conducted by Farsanilos et al 
(Farsalinos, Tsiapras, Kyrzopoulos, Savvopoulou, & Voudris, 2014). They evaluated the 
effects of e-cig use on cardiac function, more specifically to investigate the acute effects of 
using an e-cig for 7 minutes on hemodynamics parameters and myocardial function, 
compared to the effects of smoking a tobacco cigarette. The study population consisted of 
current smokers who were smoking for at least 5 years and were consuming at least 15 
cigarettes per day and e-cig users who had quit smoking and were using e-cigs for at least 1 
month. The results showed that after-use values of systolic BP, heart rate and pressure rate 
were elevated in the smoker group but not in the e-cig group. In contrast, diastolic BP 
increased almost equally in both groups.  
 
Vardavas et al conducted a study to investigate whether using an e-cigarette for short 
period of time could affect respiratory mechanics, using the experimental vs control group 
study design (Vardavas et al., 2012). The study population was composed of 30 adults 
recruited from a community setting in Athens, Greece. All subjects were current smokers 
with a minimum pack-year index of 5. The results showed that with regards to pulmonary 
oxidative stress, exhaled nitric oxide within the experimental group decreased by 16% 
after the use of an e-cig, whereas it remained unchanged within the control group. 
According to the study, decrease in exhaled nitric oxide results in respiratory impedance 
and respiratory flow resistance (similar to cigarette use). The results also showed that the 
lung airways impedance increased significantly in the experimental group whereas no 
differences were noted among control group participants. After controlling for subject’s 
baseline’s responses, the peripheral flow resistance was found to increase significantly 
after use of the e-cigs. 
 
Tzatzarakis, et al published their research in the abstracts of the 49th Congress of the 
European Societies of Toxicology (EUROTOX) (Tzatzarakis, Tsitoglou, & Chorti, 2013). The 
research was conducted to examine the acute and short term impact of active and passive 
tobacco and e-cig smoking on inflammatory markers. Ten smokers and 10 never-smokers 
completed the repeated measures controlled study. Smokers underwent a control session, 
an active tobacco cigarette smoking session, and an active e-cig smoking session. Never-
smokers underwent a control session, a passive tobacco cigarette smoking session, and a 
passive e-cigarette smoking session. Several smoking-related biomarkers including 
Interleukins (IL) 1 alpha, 1 beta, 2, 4, 6, 8, and 10 as well as vascular endothelial growth 
factor, tumour necrosis factor alpha (TNFa), monocyte chemotactic protein-1, and 
epidermal growth factor (EGF) were assessed at baseline, immediately following 
smoking/control, and one hour thereafter. The results showed that neither a brief session 
of active e-cig smoking nor a 1 hour passive e-cig smoking significantly affected the 
assessed inflammatory markers. In contrast, active tobacco cigarette smoking significantly 
increased IL2 and EGF immediately after smoking. Also, passive tobacco cigarette smoking 
increased TNFa immediately after the smoking exposure.  
 
 
 
 
 
 
 
Gaps in literature  
 
Despite the increasing popularity of e-cigs worldwide, not much research has been done 
regarding the long term effects of e-cigs on the smoking behavior of the current smoking 
population. Most of the literature deals with survey studies, soliciting personal views on 
vaping, studies analyzing potential toxins and contaminants in e-cig cartridges, reports 
profiling nicotine content, delivery, and pharmacokinetics and very few clinical and 
physiological studies investigating the effects of acute vaping. Till today, only one research 
protocol could be found which aimed to evaluate the long-term adherence to e-cigs and the 
long term efficacy of e-cigarettes in reducing and/or quitting traditional cigarette smoking. 
However, the protocol plans to follow up subjects for 5 years and the results will most 
likely not be out before 2018 (Manzoli et al., 2013).  
None of the studies mentioned above have tried to estimate or quantify the long term 
effects of e-cigs in a smoking or a non-smoking population. Most of the studies followed a 
cross-sectional survey design and used a snapshot of e-cig users at one point in time. Some 
studies observed the e-cig users for 6 months or maximum for 12 months to identify the 
effects of cessation. Based on the short term or cross sectional study designs, most of these 
studies suggest that using e-cigs or vaping could be used as a possible harm reduction tool. 
However, to trust e-cigs as a smoking-cessation agent, we need to have more 
comprehensive research evidence to make informed decisions. It is a well-known fact that 
smoking is a long term and a highly dynamic habit. It will be safe to say that if a person who 
is abstinence today, may start using e-cig tomorrow and then switch to regular cigarette in 
future. Keeping that in mind, it is important identify different behavior scenarios to model 
the long term effects of e-cig in a population. Using the evidence from currently available 
literature, it will be interesting to predict the long term net effects of e-cigs.  
 
Study Objectives 
 
The primary objective of this study was to construct a Discrete Event Simulation system to 
model the behavior and pattern of e-cig use among different smoking groups of the US 
smoking population.  The model was built and validated using the e-cig use behavior 
information available in the published literature and by seeking expert opinion from the 
field of Tobacco Regulatory Health Science. The secondary objective of this study was to 
run the simulation model to estimate the long term prevalence of e-cig use in different 
groups of the US smoking population.  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Chapter 3 
 
Methods 
 
 
 
 
 
 
 
 
 
 
 
 
Overview 
 
The primary purpose of this study was to develop a simulation model to simulate e-cig use 
behavior pattern of current smokers, former smokers and never smokers for fifteen years. 
We chose to use the technique of Discrete Event Simulation (DES) to model the e-cig use. 
The principles of good research practices for modeling studies outlined by the ISPOR task 
force (Karnon et al., 2012) were followed as closely as possible to build the model. The 
model consisted of current, former and never smokers whose behavior was simulated, 
based on existing data available in published literature.  The model included the population 
attributes and the list of events that occurred over the simulated time. The states or events 
were continuously updated through the model simulation. The uncertainty around the 
literature estimates was accounted by using stochastic simulation over deterministic 
simulation.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
What is simulation modeling? 
 
The ISPOR task force put together a report for good research practices in modeling studies 
in health care evaluation in 2012 (Karnon et al., 2012). It defined modeling as “a logical 
mathematical framework that permits the integration of facts and values, which in turn link 
these data to outcomes that are of interest to health care decision makers.” A generalized 
version of the definition summarizes simulation modeling as a computerized version of the 
system which is run over time to study the implications of the defined interactions among 
the input parameters (Weinstein et al., 2003). It helps us accurately reflect the randomness 
and interdependence of behavior and outcomes present in reality with available data and 
resources. Using simulation, we can predict the future outcomes by including time related 
events and probability distributions into the modeling framework as they occur in real life 
to obtain accurate estimates (Briggs & Sculpher, 2006; Weinstein et al., 2003).  
 
Simulation Modeling Applications in Healthcare 
 
 
Simulation modelling approaches are now widely used to assess new health care 
technologies, simulate disease or treatment pathways or simulate health behaviors. 
Generally, the modeling is needed to study consequences of any event or intervention, 
beyond the direct application of observed data (Barton, Bryan, & Robinson, 2004). In 
research, simulation modeling generally comprises of mathematical equations and analytic 
methodology that account for events that occur over time (Gold, Siegel, Russell, & 
Weinstein, 1996).  This type of modeling differs from statistical models such as regression 
models by allowing a combination of information from a variety of sources or synthesize 
data for the purpose of making a decision (Barton et al., 2004). Simulation modeling can 
also be used in conditions where cost and effectiveness parameters are compared beyond 
the data observed in a clinical trial, intermediate clinical end-points are linked to final 
health outcomes, extrapolation of the results obtained in one clinical setting to other, 
making comparisons of alternative competing interventions where direct comparisons 
have not been made in clinical trials or guiding policy decisions in absence of real data 
(Buxton et al., 1997).   
 
As the ISPOR definition mentioned above, simulation models structures are made up of 
logical framework and mathematical equations which uses the best available information 
about the system being studied, the outcomes of interest, and the risks and probabilities 
affecting each action (Stahl, 2008).  Incorporating this information into the model structure 
helps in generating evidence for or against our hypotheses, and help researchers 
understand the nature of the problem under study. We also use simulation models to aid 
our decision making by helping us make decisions under conditions of uncertainty. We can 
use it to evaluate the outcomes of different strategies, to explore the consequences of 
changes to the system and to predict how the behavior of a system with change in time.  
 
Model Selection Process 
 
 
The selection of an appropriate modelling approach is an integral step for the question 
being considered. It is represented as a flowchart in figure 1.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Can Markov model be 
built without needing 
an excessive number 
of states? 
No 
Markov model 
Yes 
Discrete event simulation 
Is history important in 
deciding the progress 
of individual in the 
model? 
Yes 
Can patient pathways be 
adequately represented 
and manageable by 
decision tree branches? 
Modeling question 
Is interaction 
between individuals 
important? 
Is individual level 
modeling needed? 
Yes 
No 
Yes 
Decision Tree 
Figure 1. Model selection flowchart (Barton et al., 2004) 
No 
Yes 
Interaction or no interaction 
The selection of the appropriate model for modeling a health care intervention should be 
made along the lines shown in Figure 1. As mentioned above, the initial consideration is 
whether the individuals in the model may be regarded as independent or not. When 
interaction is not an important issue then the choice is between decision trees, or Markov 
models. Where interaction is a significant issue in modelling, models such as DES are 
required. 
 
Cohort or individual 
The second important aspect in the model selection process the nature of the object that is 
to be modeled and conceptualizing what happens to those objects. The objects can either 
be modeled as a population (cohort or aggregate modeling) or as individuals in the 
population (individual level simulation) (Brennan, Chick, & Davies, 2006). With respect to 
conceptualizations, the problem can be represented as a series of states that the objects can 
be in, or it can be represented as events the objects can experience (Brennan et al., 2006; 
Stahl, 2008).  
 
There are two major concerns with a cohort approach. Firstly, the determination of 
proportion of population at each relevant time point. That proportion is dependent on the 
risk the population is exposed to, and that risk is affected by treatment the population is 
subject to. However in reality, the risk will also depend on patient characteristics, such as 
age, sex, smoking, and other risk factors. Hence, it is important to characterize the 
population and examine these factors individually.  
Secondly, the transition from one state to another is not random. People who are at higher 
risk, tend to move from better to worse state earlier than the rest. However, it is difficult to 
characterize these patients in terms of features that may be determinants of further risk. If 
the future risk is dependent on the duration of the time spent in the previous state, the 
estimates will be inaccurate given that the arriving populations mix into a single group and 
do not retain any memory of when they became sick (Caro, Moller, & Getsios, 2010). 
 
All the problems listed above in the cohort approach are readily solved by modeling 
individuals instead of the entire population in the aggregate. For each individual, the risk 
can be computed based on their characteristics, the risks can be easily updated over time, 
and can be recalculated based on changing history of an individual. Individual level 
modeling give us the freedom from restriction to analyze population as homogeneous 
groups with equal risks for everyone.  
 
State versus Event 
In a state-transition model, such as Markov models, the system is conceptualized as a series 
of interrelated that the population may be in. These snapshots occur at fixed, discrete time 
points called cycles. Trying to represent conditions with large number of states leads to 
different combinations of all possible outcomes, which may result in inaccuracies.  
 
The most common types of healthcare models that do not involve interaction are decision 
trees and Markov models (Karnon & Brown, 1998).  
 
 Decision Trees 
The Decision Tree has the simplest structure. All possible patient pathways are shown 
explicitly on decision tree branches, with associated probabilities and outcome measures. If 
the time frame is short and if the nature of patients’ outcome does not differ across 
strategies, a simple decision tree is an appropriate choice. Decision trees are usually 
constructed with a single decision node at the root of the tree, which then grows into a set 
of linked probability branches, one for each alternative. Although decision trees are simpler 
to understand and analyze, there is a limit to the manageable size of a tree. In case of a 
complex problems, such as a situation where the issue of interest is the survival time, using 
a decision tree becomes a cumbersome approach. To avoid an infinite number of branches 
in the tree, it is necessary to consider a different approach to model survival time with a 
different ranges.  
 
Markov Models 
Markov models are increasingly being used in complex healthcare problems. Their main 
advantage is the easy representation of recurrent events, but like decision trees they do not 
allow for interaction between individuals. Also, the transition probability depends only on 
the state in which the patient is at the start of the cycle. This is known as the Markov 
assumption. The Markov assumption does not allow the transition probability to depend 
either on the time a patient has spent in a given state, or the patient’s previous history 
before entering that state (Briggs & Sculpher, 1998). Markov models thus assume that 
patients in a given state can be treated as homogeneous groups and this homogeneity 
assumption is inherent in Markov models. For any given alternative, the proportion of 
patients in each state can be calculated sequentially for each time cycle over a period of 
simulated time. Costs are then accumulated according to the number of patients in a given 
state in each cycle. Different policies may be tested by changing the costs and transition 
probabilities. 
 
Models that account for interaction between individuals 
 
Discrete Event Simulation 
DES accounts for interaction between individuals. Also, when the outcome depends on the 
history of the patient or the continuous update of patient’s characteristics, models such as 
DES are required. DES works at an individual level and allows full representation of each 
individual’s history and the interaction between specific individuals. It can accommodate a 
more complex structure than Decision Trees and Markov models, and can still remain 
manageable in size.  
 
DES provides the luxury of overcoming the homogeneity assumptions by attaching 
attributes to the individuals within a model. The transition probabilities can be made to 
vary according to these attributes in any way that is desired. Furthermore, attributes can 
be updated while the model is running. Another advantage of DES is that it allows the 
patient to remain in a given state for a variable length of time, unlike the fixed states of 
Markov models. Also, DES uses stochastic models that include probabilistic sensitivity 
analyses to quantify the uncertainties caused due to variability in parameters whereas 
deterministic models are mathematical models where outcomes are precisely determined 
through known relationships among states and events, without any room for random 
variation. Conducting probabilistic sensitivity analyses in stochastic models also allows 
some amount of generalizability over different geographical and demographic settings.  
In a DES, the experience of individuals is modeled over time in terms of the events that 
occur and the consequences of those events. Many of the limitations and inaccuracies of 
Markov models and decision trees are easily avoided with DES.  
 
Another big advantage of DES over cohort-based models is that they can work relatively 
more efficiently with limited data availability. The quality of model is highly dependent on 
the data which is incorporated into it. In case of limited individual level data availability, a 
DES model provides a great advantage because the inadequacy of the data is not built into 
the structure of the model (Caro et al., 2010). The simulation can be designed to properly 
reflect the problem and carry out exploratory analyses with the limited data and make 
predictions. It can then incorporate additional data when it becomes available (Caro et al., 
2010). In our case, simulation will be useful as long term observational data pertaining to 
e-cig use is not available yet.  It will help us better understand and predict the vaping 
behavior (real or hypothetical) that we are trying to examine.  
 
The differences between Decision Trees, Markov models and DES are outlined in table 1 
below: 
 
 
 
  
 
Table 1. Main differences between Decision trees, Markov models and DES 
 
 
 
 
 
 
 
 
Features Decision Trees Markov Models Discrete Event Simulation 
Time horizon  Short Short and long Lifetime behavior 
# of events modeled Small  Relatively higher  High number of events 
Memory feature (Different 
risk factors over time) 
No No Accounts for risk changes 
Probabilistic sensitivity 
analysis 
Difficult Difficult Inherent in the model 
Data requirement Not good for limited 
data 
Not good for 
limited data 
Simulate large number of 
subjects with unique 
characteristics 
Accounts for interactions 
between individuals 
No No Yes 
Update of model 
population 
No No Yes 
Computational 
requirements 
Simple (Microsoft 
Excel) 
Simple (Microsoft 
Excel) 
Special software programs 
Discrete Event Simulation and its components 
 
The working structure of a DES closely replicates the course outlined in ﬁgure2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The model starts by setting the simulation clock to zero. The initial state is set by the user 
based on the system being modeled and incorporating the baseline characteristics of the 
Initialize 
 Set simulation clock 
 Initialize system state 
 Initialize event list Determine next event 
 Arrival of the entity 
 Occurrence of an event 
Advance clock 
Process event 
 Update system state 
 Update counters 
 Generate future event 
 
 Compute final 
estimates 
 Generate reports 
End run 
Figure 2. Flow diagram of the computation process for a discrete event simulation (Caro et al., 2010). 
model population. Next step is to list out all the relevant events using the logical and 
mathematical framework of the system. This will drive the flow of the model population 
and decide the change in current and future states of the model. Once the initialization step 
is over and the model is made to run, based on the individual’s characteristics and the way 
it is programmed, it determines which event will the individual will go to next. Accordingly, 
the system jumps to the next event by bringing the individual to that particular state and 
advancing the simulation model clock, which in turn records the time at which the event 
took place. Once the event is processed in the system, the change in states of the individuals 
and the system as a whole is recorded and the individual characteristics are updated. Based 
on the updated characteristics, the future states in the path of the individual is determined. 
This process is repeated until all the individuals are made to go through the entire cycle or 
until the pre-set simulation time period ends. After the simulation has ended, final reports 
are generated showing the estimated outcomes of the simulation.   
 
The fundamental components of the DES technique are described below: 
1) Entities 
A central component of DES is the entity. Entities are the items that flow through the 
simulation, smokers in our case. Smokers have attributes (e.g. age, sex, race, smoking 
history), with each individual having a speciﬁc value for each characteristic. These values 
are defined at the start of the simulation and are updated as events take places such as age 
increases, initiating e-cig use, or quit attempts. These updates can happen at particular 
points in time. The model update is decided on the basis of the structure of the problem.  
 
2) Events 
The second major element of the simulation is the events that drive the entities. An event 
can be deﬁned as anything that happens during the simulation. Thus, it can be the 
occurrence of a quit attempt, initiation of e-cig, relapse or just aging in the model. Events 
can happen in any logical sequence and even simultaneously. They can recur if that 
happens in reality. Events change the course of individuals’ experience by inﬂuencing their 
attributes and occurrence of future events with no restriction on memory. For example, the 
initiating of e-cig can depend on previous use but can also be altered by making a quit 
attempt in future. The rates at which events occur can take any functional form supported 
by the data or assumptions. They can be dependent on any attributes or variables and 
these functions can change over time as appropriate. 
 
3) Time 
The third important component of a DES is time. A simulation clock keeps track of the 
passage of time in the model. This permits the modeler to clearly signal the start and end of 
the simulation and to create internal time periods such as the length of staying in a 
particular state. By making time explicit, a DES allows more ﬂexibility than Markov models 
and Decision trees. Time moves continuously and the units can be minutes, days, months or 
whatever is convenient. However, since the progression of simulation depends on events, 
the simulation clock is advanced to the time when the next event will occur. 
 
 
 
4) Means of Execution 
The ﬁnal component is the means to execute the simulation, following a desired logic and 
carrying out all the calculations. The execution begins by formulating the question in detail, 
providing a description of the system that is to be modelled, specifying the details that 
pertain to the condition in question. Following that, the model is designed conceptually in 
the form of an influence diagram. Once the concept has been validated with help from 
relevant experts, data are fit to the model. 
 
5) Actual simulation 
Once the model is coded in software and debugged, the analysis in a DES proceeds by 
specifying the initial system conditions (i.e. starting values for all attributes and variables) 
and simulation settings (e.g. duration, time units, number of replications). The software 
then carries out the simulation by applying the logic to each entity (patient) using random 
numbers to obtain specific values from assigned distributions and determine whether 
probabilistic events occur at a given time to a given patient. Thus, a DES is an individual 
patient, stochastic simulation (Caro et al., 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
As explained in the overview section of this chapter, we decided to construct a DES model 
to simulate the behavior of e-cig users in the US. The description of the data sources, model 
parametrization, simulation pathway and handling uncertainty is described as follows. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The E-cig model  
 
Generating the model population 
To generate the model population, we used publicly available data from the cross-sectional 
National Health Interview Survey (NHIS), a nationally representative multistage household 
survey of the civilian noninstitutionalized population of the United States. The National 
Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC) 
has conducted the NHIS annually since the 1950s to monitor the nation's health at both the 
household/family level (e.g., type of living quarters, family size, and total combined family 
income) and the individual level (e.g., various medical/health conditions, risk factors, and 
access to care). The main objective of the NHIS is to monitor the health of the US population 
through the collection and analysis of data on a broad range of health conditions. The 
survey also collects current data on many demographic and socioeconomic characteristics 
(NCHS, 2012). 
The NHIS covers the civilian population residing in the United States at the time of the 
interview. It is a cross-sectional household interview survey and the sampling plan follows 
a complex, multistage probability sample that incorporates stratification, clustering, and 
oversampling of some subpopulations (e.g., Black, Hispanic, and Asian) in some years (MPC, 
2011; NCHS, 2012). Because of the complex sampling design of the NHIS, sampling weights 
are constructed so that each unit (survey respondent or household) can be inflated or 
expanded to represent other individuals or households in the United States (NCHS, 2012).  
The NHIS questionnaire contains four major components: Household, Family, Sample 
Adult, and Sample Child. The Household component collects demographic information on 
all of the individuals living in a particular house. The Family component collects additional 
demographic information on each member from each family in the house and collects data 
on topics including health status and limitations, injuries, healthcare access and utilization, 
health insurance, and income and assets. The Family Core component allows the NHIS to 
serve as a sampling frame for additional integrated surveys as and when needed. From 
each family in the NHIS, one sample adult and one sample child are randomly selected and 
information on each is collected with the Sample Adult Core and the Sample Child Core 
questionnaires. Because some health issues are different for children and adults, these two 
questionnaires differ in some items but both collect basic information on health status, 
health care services, and health behaviors. Its protocol and administration have been 
approved by the NCHS's Research Ethics Review Board, and all NHIS participants provide 
informed consent (NCHS, 2012). 
For the purpose of our model population, we pooled the data for 2011, 2012 and 2013 to 
generate a recent national estimate of the US population with specific demographic and 
smoking-related characteristics. Each data file contained household, family, and person 
record identifiers that made merging the data files possible. Once the data files were sorted 
by the household, family, and person record identifiers (coded as HHX, FMX and FPX in 
NHIS, respectively), the Household, Person, and Sample Child data files were merged, for 
each of the three years. Variable names were changed from one year to another when 
required. The data across the years were combined or concatenated to increase the 
number of observations or respondents and thus increase the precision of estimates. The 
three years’ worth of merged data files joined one after the other (concatenation). New 
weights were constructed to adjust for combining data years. For three years of data, the 
new weights were calculated by dividing the original weights by 3 to give the final weight 
of every individual in the sample.  
The pooled dataset had 86,402 individuals who had complete information on their 
demographic characteristics and smoking behavior. We classified a respondent's cigarette 
smoking behavior by his/her answers to questions about cigarette smoking status and 
smoking cessation attempts based on an existing NHIS recoded variable with six response 
levels: current smoker, recent former smoker, and never smoker.  Respondents that 
reported having smoked at least 100 cigarettes in their entire life and were currently 
smoking every day or some days at the time of interview, were classified as current 
smokers (CS). Respondents reported smoking at least 100 cigarettes during their lifetime 
but currently did not smoke at least for the past 12 months, were classified as former 
smokers (FS). FS were further classified into recent former smokers or late former 
smokers. Recent former smokers were those former smokers who had stopped smoking 
less than 12 months ago. Late former smokers were those former smokers who had 
stopped smoking over a year ago.  
 
Respondents reported not having smoked at least 100 cigarettes in their life and were not 
currently smoking for the past 12 months, were classified as never smokers (NS). This 
method of smokers’ classification has been recommended by NCHS and is used in earlier 
studies done on smoking population (Mehta & Preston, 2012).   
Descriptive analyses was run on the sample to calculate the frequency distribution of 
population demographic and smoking characteristics.  The demographic categories 
included age (<21, 21-35, 36-50, 51-65, >65), gender (male, female), race (white, black, 
other), and education level (less than high school, high school, college). The smoking-
related categories included years of regular smoking (for current smokers), at least one 
quit attempt in the past 12 months (for current smokers) and nicotine dependence score 
(for current smokers). The information on nicotine dependence had to be utilized from a 
different source. We used the estimates of a matched sample, from a web based survey on 
current and former smokers in the US (Yeomans et al., 2011). 
Probability estimates related to e-cig use  
The probabilities of current e-cig use associated with different demographic and smoking 
characteristics, among different smoking categories of the US population were derived 
from the prevalence estimates published in several cross-sectional and longitudinal e-cig 
studies done in the US.  
The e-cig prevalence estimates associated with age, gender, race, education level for 
current, former and never smokers were utilized from the Knowledge Networks survey 
data, which was commissioned by the University of California, San Diego (Zhu et al., 2013). 
The survey collected information on smoking history and cigarette use, perceptions about 
different tobacco products and quitting aids, attitudes toward tobacco control efforts, and 
beliefs and ideation about the process of quitting smoking. The study sampled the smokers, 
former smokers and never smokers from the panel in a way such that the three smoking 
status groups were approximately equal in size. The final survey sample consisted of 3,111 
current smokers, 3,676 former smokers and 3,254 never smokers. Following the same 
classification as our NHIS sample, current smokers (CS) were defined as those who had 
smoked at least 100 cigarettes in their lifetime and were still smoking some days or every 
day at the time of survey administration. Former smokers were defined as smokers who 
smoked at least 100 cigarettes in their lifetime and were not smoking at the time of survey 
administration. Former smokers were further classified into recent former smokers (RFS) 
and late former smokers (LFS). Former smokers were classified as RFS if they smoked their 
last cigarette within the time period of 1 year or less, and as LFS if they smoked their last 
cigarette over 1 year ago. Never smokers (NS) were defined as those who had not smoked 
100 cigarettes in their lifetime (Zhu et al., 2013).  
 
Use of e-cigs was also assessed in multiple questions. First, respondents were asked if they 
had ever heard of e-cigs. Next, those who had heard of e-cigs were asked if they had ever 
tried an e-cig. Those who answered yes were considered ever users. Ever users were also 
asked if they had used e-cig multiple times in the last 30 days. Those who answered yes, 
were considered current e-cig users (Zhu et al., 2013).  
 
Along with the prevalence estimates associated with demographic characteristics, the 
Knowledge Networks Panel survey data also provided related standard errors and 95% 
confidence intervals which were used to carry out sensitivity analyses for the simulation 
model. We did not use the prevalence estimate for ever e-cig users as published studies 
have indicated that ‘ever use’ is not the accurate measure of e-cig prevalence (Adkison et 
al., 2013; Bell & Keane, 2012). Mostly, ever users have been known to try e-cig once and not 
continue after that. Also, we wanted to use a conservative estimate in our simulation model 
to predict the outcomes. Hence, current e-cig use estimates were chosen over ever e-cig 
use. 
 
Zhu et al did not report the prevalence associated with e-cig users below 18 years. Since 
the age group of 6-18 years has been associated with a high use of e-cig in the US (Agaku et 
al., 2014), we used another study to obtain prevalence estimates of age category 6-20 
years. The study analyzed a sample of 3,912 high school and middle school students of 
current and recent former cigarette smokers and e-cig users (Camenga et al., 2014). The 
students were attending high schools in Connecticut and New York and were asked similar 
questions as in the Knowledge Networks survey.  
 
For the probability associated with making a quit attempt, we used estimates from the 
Legacy Longitudinal Smoker Cohort (LLSC) survey data (Pearson et al., 2012). The LLSC 
collected data on a large cohort of current smokers and recent former smokers (n= 5616) 
living in the US, and was used to obtain demographic and point estimates for awareness, 
use, and harm perceptions associated with e-cigs.  
 
The e-cig use associated with the nicotine dependence score and cigarette per day use, 
were derived from estimates obtained from the International Tobacco Control Four 
Country Survey (ITC-4) data, conducted between 2002 and 2011 (Kasza et al., 2014). The 
survey population consisted of 6,110 adult smokers in the US, Canada, UK and Australia 
and it examined the demographic and smoking-related predictors of use of unconventional 
tobacco products (i.e., other smoked tobacco products, smokeless tobacco products, 
unconventional cigarettes, and e-cigs). We used the estimates reported for the US 
population. The prevalence estimates along with the source for current, recent former, late 
former and never smokers are summarized in tables 6, 7, 8 and, 9 respectively, in the 
results section. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Model parametrization 
 
The model was structured in terms of the specific events that individuals experience over 
the course of the simulation. The events and the attributes assigned to the model 
population were chosen after reviewing the e-cig literature and choosing the variables 
which had statistically and practically significant association with the use of e-cig among 
current, former and never smokers. Most studies indicated that age, gender, race, education 
level, years of smoking, past quit attempts, and nicotine dependence showed a significant 
association with the use of e-cig among current cigarette smokers (Kalkhoran, Grana, 
Neilands, & Ling, 2015; Kasza et al., 2014; King et al., 2013; McMillen, Gottlieb, Shaefer, 
Winickoff, & Klein, 2014). Accordingly, each individual was assigned a set of unique 
attributes which were corresponding to their baseline characteristics at the start of the 
simulation. These attributes or characteristics, were updated throughout the simulation, 
depending on the subject’s course through the model. The set of events in the simulation 
correspond closely to the behavior of e-cig users when they switch to e-cigs.  
 
At the beginning, 100,000 smokers were generated by using the “Create” module from the 
Arena toolbar.  The smokers were created and an exponential distribution was assigned to 
their arrival in the system. Once the model population was generated, the next step was to 
send them into one of the four branches; CS, RFS, LFS, and NS. The percent of people sent 
into each depended on the real live distribution of smokers obtained from the NHIS data. 
Next, the smokers were assigned baseline attributes using the “Assign” module. We 
assigned age, gender, race, education level, nicotine dependence, years of smoking, 
cigarette per day use, and past quit attempts to each initial smoker. We then recorded each 
smoker's yearly progress based on these assigned characteristics. 
Age 
The age assignment was done using the frequency distribution from the NHIS survey. The 
attribute “Age” was categorized into 5 age groups, which matched the data available for e-
cig use. A continuous probability distribution was assigned to the Age attribute. 
Additionally, an original age attribute “AgeOrig” was assigned in the simulation to keep the 
track of the smokers’ increasing age within the system. Finally, another attribute “Age 
Group” was assigned based on current age in the model.  
Gender 
Similar to the age assignment, the “Gender” attribute was assigned using the frequency 
distribution from the NHIS survey. The assignment was done at two levels; 1-Male, 2-
Female, and a discrete probability distribution was assigned to this attribute. 
Race 
The smokers’ race was assigned as a 3-level attribute named “Race”. Derived from the NHIS 
sample, level 1 was for “white”, 2 for “black” and 3 for “others”.  The Race categorization 
was done to match the e-cig use data. Similar to the Gender attribute, Race was assigned a 
discrete distribution.  
 
Education 
The education level was assigned as a 3-level attribute named “Education”. Derived from 
the NHIS sample, level 1 was for smokers who had did not have a high school diploma, 2 for 
smokers who had at least a high school diploma and 3 was for smokers who had at least a 
college degree. The Education categorization was done to match the e-cig use data. 
Education was also assigned a discrete probability distribution.  
Nicotine Dependence score 
The next assignment was done using the “Assign” module again and it was used to assign 
the nicotine dependence score attribute “FTND score” to current smokers. The 3-level 
attribute derived the values from the matched sample from the web-based survey of US 
current smokers (Yeomans et al., 2011). It was assigned a discrete probability distribution. 
Previous Quit attempts 
The assignment of previous quit attempts was done using the distribution from the NHIS 
sample. The 2-level attribute was named “PrevQuit” and it had 0 for smokers who did not 
make even a single quit attempt and 1 for smokers who had attempted to quit at least once 
in their life. It was assigned a discrete probability distribution. Along with the “PrevQuit” 
attribute, another attribute named “CountQuitAttempt” was assigned in the system. The 
original value of this attribute was assigned as “PrevQuit” and its value was supposed to 
increase with every quit attempt a smokers makes in the simulation. Essentially, this step 
created the history of quit attempts before the current smokers entered the simulation 
model.  CountQuitAttempt attribute was used to add the new quit attempts to the quit 
attempts already made in the past (PrevQuit) of a current smoker, and there by changed 
the individual risk associated with the quit attempts in the system. 
Assigning baseline probabilities and distributions 
The probability for each event in the simulation model was assigned using the “Variable” 
module. A specific probability within each level of attribute, for every attribute was 
assigned which was responsible for events experienced by that individual smokers through 
the simulation. The probabilities were derived from the e-cig prevalence estimates 
discussed above.  
Two specific distributions were assigned to the probabilities in the model, Continuous and 
Discrete. The Continuous distribution in Arena returns a sample from a user-defined 
continuous distribution, which in this case was the age distribution. Pairs of cumulative 
probabilities and associated values are specified, and then the sample returned has a real 
number between associated values and with corresponding cumulative probabilities. The 
continuous empirical distribution is often used to incorporate actual data for continuous 
random variables directly into the model.  
The Discrete function in Arena returns a sample from a user-defined discrete probability 
distribution. The distribution is defined by the set of n possible discrete values that can be 
returned by the function and the cumulative probabilities. In our study, model inputs such 
as gender (1, 2), race (1, 2, 3), or education level (1, 2, 3) had discrete distribution.  The 
discrete empirical distribution is often used to incorporate discrete empirical data directly 
into the model.  
Simulation Pathway 
This section presents the events that determine whether or not simulated smokers will 
become an e-cig user or not. For current smokers, these events were: 
 Using e-cig 
 Making a quit attempt 
 Relapse 
 Quitting 
 Ageing 
 Leaving the model 
Once the smoker entered into the model, he/she was assigned the baseline attributes, 
associated probabilities and the corresponding probability distributions. After that, the 
smokers moved ahead and were given a choice to initiate using e-cig. The decision to use or 
not use came from the probability equations discussed below.  
If the smoker decided to start using e-cig, he or she was given a chance to quit using e-cig 
within that same year. Around 48% made a quit attempt after using e-cig once and did not 
use it again. However, 52% continued using e-cig. This estimate was used from the study 
conducted by Kasza et al where the smokers who became e-cig users were asked after 1 
year if they had made any attempts to stop smoking after using e-cig (Kasza et al., 2014).  
Smokers who made a quit attempt the same year, were evaluated if they made a relapse to 
using e-cig within the same year. Based on the same study, 9% smokers who attempted a 
quit attempt did not make a relapse and stayed a quitter (Kasza et al., 2014). These quitter 
were then assigned the status of “Former smoker” and their risk of e-cig use also were 
changed accordingly. Smokers who continued using e-cigs (relapse) were allowed to 
remain the in the loop and age in the simulation process. Next year, these smokers were 
made to pass through quit attempt module again to see if they made a quit attempt next 
year. Smokers who made a relapse were evaluated for the number of quit attempts and 
their age.  
With each failed quit attempt, the probability of using the e-cig increased by 13% according 
to the literature (Pearson et al., 2012). We factored this scenario by recording the new quit 
attempts made after initiating the e-cig to the “CountQuit” attribute. That way, the new quit 
attempts were added to the history of previous quit attempts, and accordingly changed the 
overall probability of using the e-cig again in the simulation model. We did not want the 
probability to cross over 100% with several quit attempts, so we limited the number of quit 
attempts to 4. Anyone who made 4 quit attempts in the model, was counted as a regular e-
cig user and allowed to exit the model.  
Finally, smokers who did not initiate e-cig in the first year were allowed to age and 
assigned two new risks for initiating e-cig next year. First, as they aged a new risk of using 
e-cig was assigned based on their new age. Second, after 7 years into the simulation, every 
year the overall risk was made to reduce by 1% of the preceding year. We did this because 
we assumed that the initiating probability of e-cig will reduce in future due to variety of 
reasons ranging from new policies or regulations to the launch of new unconventional 
tobacco products. Also, since e-cig has been launched fairly recently, currently it is not 
regulated by any agency. However, in a few years, perhaps the FDA will control the sale of 
e-cigs to young adults, or another unconventional tobacco product will be launched, or the 
consumer will have enough information about e-cig to make a decision, so its prevalence 
will wane down (Foulds et al., 2011). Hence, we factored this in by reducing the overall risk 
each subsequent year. Please see figure 3 for the working structure of the DES model. We 
used the risk reduction of 1% from a recent study done to examine the potential impact of 
price-related and tax-related policies on e-cigs use by assessing the own and cross-price 
elasticity of demand for e-cigs (Huang, Tauras, & Chaloupka, 2014). The study reported a 
10% increase in price would reduce sales of e-cigs by approximately 12% or 10%. Taking 
the conservative approach, we first reduced the risk by 1% each year after the 7th year, and 
then tested the impact by increasing it to 3% and 5% each year in sensitivity analyses. 
Similarly, we tested the impact of timing of the policy by applying it at 5 years, 10 years and 
not applying it at all.   
Cumulative probability equation 
The ideal way to calculate the probability of an event happening is to run a linear 
regression on the model parameters to get the relationship and mutually exclusive 
probabilities. According to the probability theory, events E1, E2, En are said to be mutually 
exclusive if the occurrence of any one of them implies the non-occurrence of the 
remaining n − 1 events. Therefore, two mutually exclusive events cannot occur at the same 
time. Formally said, the intersection of each two of them is empty (the null event): A ∩ B = 
0. In consequence, mutually exclusive events have the property: P(A ∩ B) = 0 
(Beerenwinkel & Siebourg, 2012). 
However, due to unavailability of individual level data related to e-cig, we were unable to 
use mutually exclusive probabilities. Instead, we used non-mutually exclusive event 
probabilities. Non-mutually exclusive events are events in which there is some overlap. 
When P(A) and P(B) are added, the probability of the intersection is added twice. To 
compensate for that double addition, the intersection needs to be subtracted. In other 
words, the probability of one or both events occurring is denoted P(A ∪ B) and in general it 
equals P(A) + P(B) – P(A ∩ B) (Beerenwinkel & Siebourg, 2012). Hence, we added all the 
individual probabilities associated with e-cig use and subtracted the intersections from the 
total sum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outcome Measures 
 
Structural simulation of e-cig users’ behavior 
 
One of the broader outcome of this study was to make an exploratory model which uses the 
currently available literature in structurally capturing the behavior of current, former and 
never smokers in terms of e-cig use. The model structure accounted for change in smoking 
habits, temporary or permanent use of e-cig, quitting behavior and relapse to smoking.  
 
E-cig prevalence among current, former and never smokers  
 
Another important outcome of this study was to estimate the national prevalence of e-cig 
use among the population of current cigarette smokers, past cigarette smokers and never 
smokers, and plot the estimates against time. The prevalence was also estimated in the sub 
population groups, specifically within different age groups, gender, race, and education 
level. The model was run for the period of fifteen years and the prevalence was plotted 
against time for each of the fifteen years. 
 
 
 
 
 
 
Simulation runs 
 
The model ran several sets of analyses to introduce the variation around the estimates. 
Specifically, the model was run using populations of 100,000 current, former and never 
smokers. Every simulation was for 100 replications to obtain confidence intervals when 
examining changes in the smoking groups.  
 
Calculating smoking prevalence 
The prevalence was calculated using the formula below: 
 The average number of simulated CS, recent FS, late FS and NS who were recorded 
as e-cig users at the end of the simulation, for each time period. 
 The size of the simulated smoking population (N=100,000) which entered the 
model. 
 Since it is a population model, each year the number of people being born and dying 
were taken care by implementing the equation: 
 
 
 
 
 
 
The birth rate (br) adds to and the death rate (dr) subtracts from the population at 
each point, and the rates were obtained from the US census bureau website (US 
Census Bureau, 2014). 
 
Population t+1 = Population t + br * Population t – dr * Population t 
  Prevalence was then calculated by dividing the average number of e-cig users 
during the specified time period by the size of the simulated population.  
The formula for calculating prevalence is shown below. 
Prevalence= 
E-cig users at the end of each time period 
Size of simulated population during the same time period 
X 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Model validation 
  
The model was validated by a variety of methods. First, the model was tested for internal 
validation by using null and extreme input values to test whether they produce the 
expected outputs. This helped in verifying that the mathematical equations were 
calculating the correct values. Secondly, it was checked for debugging that included getting 
the program code examined for syntactical errors and test of reproducibility using 
equivalent input values. Debugging was performed by getting the programming code 
verified by Dr. Jaime Carro (Evidera) and Dr. Jorgen Moller (Evidera), who are experts in 
DES programming and have been making DES models in healthcare evaluation for over 10 
years. Thirdly, the structural validity was conducted by getting the model structure 
examined by experts in the area of e-cig use. It ensured that the model incorporated all the 
feasible behavior scenarios in the model structure. Additionally, the model structure was 
validated by comparing our model structure with other published DES models (Gestios et 
al, 2013; Howard et al, 2008) which looked at cigarette smoking behavior and smoking 
cessation strategies, and the scenarios applicable to smoking behavior were incorporated 
in our model structure.  Fourth, the model was tested for internal consistency by verifying 
that the mathematical probability equations used in the model were correct based on the 
probability theory and by seeking expert opinion from professionals in modeling and 
systems analyses. This was done by getting model structure verified by Dr. Edward Boone 
(VCU) and Marc Botteman (Pharmerit), who are experts in the area of system analysis. 
They checked the flow of smokers through different branches and helped in authenticating 
the output of our model.  
 We believe that getting our model verified by external DES and system analysis experts 
also increased the face validity of the model. Face validation helped to ensure that the 
model was constructed and used in accordance with the most current scientific and best 
available evidence. This enhanced the credibility and the acceptance of results. Moreover, 
we were able to perform limited amount of external validity which means comparing the 
model’s results to actual information in the real world. It involved comparing our model’s 
first year’s results with the most recent CDC reports on e-cig prevalence in the US 
population. Due to data limitation, we could not perform an independent validation 
whereby data used to validate comes from a source other than the one used to build the 
model.  
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Figure 3. Working flowchart of the model structure. 
Model assumptions 
 
 The proportion of smokers using e-cigs in each sub-group was assumed as 
probabilities associated with the use of e-cig. 
 The decision to use or not to use an e-cig each year in the model, depended only 
upon their baseline demographic and smoking characteristics and associated 
probabilities.  
 The probability associated with making a quit attempt toward e-cig were assumed 
to be similar to the probability associated with quitting regular cigarette. 
 Smokers inside the simulation model were not all allowed to use any external 
smoking cessation source such as primary or secondary smoking cessation 
treatments. Also, they were assumed to be willing to try e-cig as a smoking cessation 
tool. 
 The quit attempt made inside the simulation model was assumed to be associated 
only with the use of e-cig and not because of external factors such as smoker’s 
intention, health risks, or cost changes. 
 In never smokers, a person was assumed to not initiate using e-cig after 35 years of 
age.  
 The nicotine dependence score derived from the matched sample of the web based 
survey smokers’ profile were assumed to be the nicotine dependence score of 
current smoker population created from NHIS. 
 The effect of e-cig policies and regulations which will come into place in future was 
assumed to be 1% and was factored in the model by structuring a branch for non e-
cig users which reduced the overall probability of using e-cig by 1% each 
subsequent year.  
 It was assumed that the smoking environment will not have any drastic change 
which will affect the initiation and the use of e-cig for the next 15 years. 
 Smokers over 85 years were assumed to die and allowed to exit the model.  
 The number of maximum quit attempts a person could make in the simulation was 
capped at 4. 
 All e-cig users were assumed to be using a nicotine containing e-cigs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Chapter 3 
 
Results 
 
 
 
 
 
 
 
 
 Model Population Descriptive Analyses  
 
Demographic 
attributes 
N Weighted N Weighted % 
Standard 
error 
Age     
<21 years 60 839069 1.825 0.257 
21-35 years 1209 15951411 34.701 1.063 
36-50 years 1184 15583632 33.901 0.808 
51-65 years 944 10921864 23.760 0.898 
>65 years 376 2671325 5.811 0.449 
     
Gender     
 Male 2179 25536741 55.554 1.089 
 Female 1594 20430560 44.445 1.089 
     
Race     
White  1813 31386247 68.279 2.521 
Black  944 6412197 13.949 1.385 
Other  1016 8168857 17.771 1.603 
     
Education     
No high school 
diploma 
391 2958378 9.615 0.692 
High school 
diploma 
1079 13470898 43.781 1.400 
Any college 1032 14339077 46.603 1.504 
 
 
 
 
 
 
Table 2(a). Demographic attributes of the national sample of current cigarette smokers. 
 
Smoking related attributes 
CPD (Means, SD) 11.87 (8.80) 
Years of regular smoking 
(Means, SD) 27.02 (15.69) 
At least 1 quit attempt in past 12 
months (%) 46.97  
 
 
 
Table 2(a) presents the baseline characteristics of the current cigarette smokers’ 
population in the US. The weighted N and the weighted percent indicate the nationally 
representative sample. The age-wise distribution indicated that most of the current 
smokers were in the age-group 21-35 years old (34.70%), followed by the age group of 
36-50 years old (33.90%). Around 55.56% of CS were males, 68.28% white and 46.60% 
had a college degree. Table 2(b) presents the distribution with respect to the smoking 
related attributes. Mean (SD) cigarette per day (CPD) use and mean (SD) years of 
regular smoking were found to be 11.87(8.8) and 27.02(15.69), respectively. Around 
46.97% of current smokers had attempted at least 1 quit attempt in the past 12 months.  
 
 
 
 
 
 
 
 
 
Table 2b. Smoking related attributes of the national sample of current cigarette smokers. 
Demographic attributes N Weighted N Weighted % 
Standard 
error 
Age     
<21 years 18 271816 0.515 0.163 
21-35 years 496 8135462 15.427 0.976 
36-50 years 774 12341650 23.404 1.126 
51-65 years 1279 16893561 32.036 0.923 
>65 years 1694 15089969 28.616 1.138 
     
Gender     
 Male 2560 29172122 55.321 1.082 
 Female 1701 23560335 44.679 1.082 
     
Race     
White NH 2323 41275536 78.273 1.710 
Black NH 730 3814939 7.234 0.781 
Other NH 1208 7641983 14.491 0.835 
     
Education     
No high school diploma 552 3452526 10.832 0.955 
High school diploma 949 11874463 37.255 1.836 
Any college 1189 16546498 51.913 2.020 
 
 
Table 3 presents the baseline characteristics of the recent former cigarette smokers’ 
population in the US. Most of the smokers were in the age group 51-65 years old 
(32.03%) followed by smokers in the age group >65 years old (28.61%). The age group 
of <21 years old had the least proportion of smokers (0.52%). Around 55.32% of recent 
FS were males, 78.27% white and 51.91% had a college degree.  
 
 
 
Table 3. Demographic attributes of the national sample of recent former cigarette smokers. 
Demographic attributes N Weighted N Weighted % 
Standard 
error 
Age     
<21 years 9 152956 0.323 0.145 
21-35 years 359 6026529 12.753 0.924 
36-50 years 676 10743499 22.734 1.108 
51-65 years 1187 15758480 33.347 0.898 
>65 years 1630 14574125 30.841 1.229 
     
Gender     
 Male 2336 26293298 55.640 1.030 
 Female 1525 20962291 44.359 1.030 
     
Race     
White NH 2124 37248217 78.822 1.662 
Black NH 653 3347783 7.084 0.779 
Other NH 1084 6659589 14.092 0.812 
     
Education     
No high school diploma 511 3202542 11.298 1.041 
High school diploma 848 10604450 37.413 1.903 
Any college 1074 14537169 51.288 2.017 
 
 
Table 4 presents the baseline characteristics of the late former cigarette smokers’ 
population in the US. Similar to recent FS, most of the late FS were in the age group 51-
65 years old (33.35%) followed by smokers in the age group >65 years old (30.84%). 
The age group of <21 years old had the least proportion of smokers (0.32%). Around 
55.32% of late FS were males, 78.82% white and 51.28% had a college degree.  
 
 
 
Table 4. Demographic attributes of the national sample of late former cigarette smokers. 
Demographic attributes N Weighted N Weighted % 
Standard 
error 
Age     
<21 years 231 3340197 2.771 0.403 
21-35 years 2679 35530624 29.484 0.940 
36-50 years 2574 37034518 30.732 0.880 
51-65 years 2199 27546725 22.859 0.662 
>65 years 1980 17053907 14.151 0.507 
     
Gender     
 Male 3907 50751366 42.115 0.598 
 Female 5756 69754605 57.884 0.598 
     
Race     
White NH 3637 76205275 63.237 2.208 
Black NH 2125 14735580 12.228 1.090 
Other NH 3901 29565116 24.534 1.249 
     
Education     
No high school diploma 1189 7503846 11.060 0.755 
High school diploma 2023 24466045 36.061 1.052 
Any college 2681 35875006 52.878 1.173 
 
 
Table 5 presents the baseline characteristics of the never smokers’ population in the US. 
Most of the NS were in the age group 36-50 years old (30.73%), followed by smokers in 
the age group 21-35 years old (29.48%). The age group of <21 years old had the least 
proportion of smokers (2.78%). Around 57.88% of NS were females, 63.23% white and 
52.88% had a college degree.  
 
 
Table 5. Demographic attributes of the national sample of never cigarette smokers. 
Tables 6, 7, 8 and 9 show the results of the literature review done to obtain demographic 
and smoking behavior related risks associated with the initiation of e-cig. The tables list the 
assignment of probabilities associated with initiating of e-cig use, based on each level of 
population attribute for current, recent former, late former and never smokers, 
respectively. Along with that, the columns show the assigned probability distributions, data 
source and the studies which analyzed the data and reported those estimates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Model Input Parametrization  
 
 
 
 
Table 6 presents the mutually unexclusive probabilities associated with the initiation of 
e-cig based on different attributes, in current smokers. The highest probability of 
Parameters 
E-cig use 
probability 
Assigned probability 
distribution 
Data Source 
Age, years  Continuous School students  survey  in Camenga et al 
<21 0.14  NY and  CT, Knowledge Zhu et al 
21-35 0.072  Networks Panel  Survey  
36-50 0.059    
51-65 0.082    
>65 0.002    
Gender  Discrete Knowledge Zhu et al 
Male 0.049  Networks Panel  Survey  
Female 0.086    
Race   Discrete Knowledge Zhu et al 
White  0.075  Networks Panel  Survey  
Black 0.062    
Other 0.014    
Education status   Discrete School students  survey  in Camenga et al 
less than high school 0.088  NY and  CT, Knowledge Zhu et al 
more than high school 0.066  Networks Panel  Survey 
 
any college 0.045    
FTND Score   Discrete International Tobacco Kasza et al 
Low 0.016  Control Four Country  
Medium 0.014  Survey (ITC-4) data  
High 0.021    
Quit attempts within past 
12 months   Discrete Legacy Longitudinal 
 
Pearson et al 
None 0.013  Smoker Cohort (LLSC)  
At least 1 0.037  survey data  
Table 6. E-cig initiating probabilities and assigned distribution for current smokers. 
initiation was found to be in the age group of <21 years (0.35) compared to other age 
groups. Females (0.56), whites (0.48), and those who had less than high school 
education (0.49) had a higher probability than their counterparts. With respect to 
smoking-related attributes, smokers having a high nicotine dependence (0.52) and 
those who had at least one quit attempts in the past (0.64) had a higher probability than 
their counterparts.  
 
 
 
 
Parameters 
E-cig use 
probability 
Assigned probability 
distribution 
Data Source 
Age, years  Continuous School students  survey  in Camenga et al 
<21 0.100  NY and  CT, Knowledge Zhu et al 
21-35 0.073  Networks Panel  Survey  
36-50 0.059    
51-65 0.082    
>65 0.026    
Gender  Discrete Knowledge Zhu et al 
Male 0.049  Networks Panel  Survey  
Female 0.076    
Race   Discrete Knowledge Zhu et al 
White  0.076  Networks Panel  Survey  
Black 0.062    
Other 0.028    
Education status   Discrete School students  survey  in Camenga et al 
less than high school 0.088  NY and  CT, Knowledge Zhu et al 
more than high school 0.066  Networks Panel  Survey 
 
any college 0.045    
Table 7. Baseline attributes, corresponding probabilities and assigned distribution for recent former smokers. 
Table 7 presents the probabilities associated with the initiation of e-cig in recent former 
smokers. Similar to current smokers, the highest probability of initiation was found to 
be in the age group of <21 years (0.31), females (0.51), whites (0.44), and those who 
had less than high school education (0.51).  
 
 
 
 
 
 
 
Parameters 
E-cig use 
probability 
Assigned probability 
distribution 
Data Source 
Age, years  Continuous School students  survey  in Camenga et al 
<21 0.039  NY and  CT, Knowledge Zhu et al 
21-35 0.011  Networks Panel  Survey  
36-50 0.004    
51-65 0.032    
>65 0.001    
Gender  Discrete Knowledge Zhu et al 
Male 0.002  Networks Panel  Survey  
Female 0.008    
Race   Discrete Knowledge Zhu et al 
White  0.008  Networks Panel  Survey  
Black 0.001    
Other 0.003    
Education status   Discrete School students  survey  in Camenga et al 
less than high school 0.002  NY and  CT, Knowledge Zhu et al 
more than high school 0.001  Networks Panel  Survey 
 
any college 0.007    
Table 8. Baseline attributes, corresponding probabilities and assigned distribution for late former smokers. 
Table 8 presents the probabilities associated with the initiation of e-cig in late former 
smokers. The highest probability of initiation was found to be in the age group of 21-35 
years (0.36), females (0.51), whites (0.41), and those who had college level education 
(0.43).  
 
 
 
Table 9 presents the probabilities associated with the initiation of e-cig in never 
smokers. Since we assumed that never smokers will not initiate e-cig use after 35 years, 
we only used probabilities of <21 years and 21-35 years age groups. The age group <21 
years (0.58), females (0.53), whites (0.47), and those who had college level education 
(0.45) had a higher probabilities than their counterparts.  
 
Parameters 
E-cig use 
probability 
Assigned probability 
distribution 
Data Source 
Age, years  Continuous School students  survey  in Camenga et al 
<21 0.011  NY and  CT, Knowledge Zhu et al 
21-35 0.007  Networks Panel  Survey  
     
Gender  Discrete Knowledge Zhu et al 
Male 0.005  Networks Panel  Survey  
Female 0.007    
Race   Discrete Knowledge Zhu et al 
White  0.006  Networks Panel  Survey  
Black 0.006    
Other 0.001    
Education status   Discrete School students  survey  in Camenga et al 
less than high school 0.008  NY and  CT, Knowledge Zhu et al 
more than high school 0.006  Networks Panel  Survey 
 
any college 0.004    
Table 9. Baseline attributes, corresponding probabilities and assigned distribution for never smokers. 
  
                                                     
 
 
Figure 4. E-cig use simulation model
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E-cig Prevalence in Current Cigarette Smokers 
 
 
 
 
 
 
 
Figure 5 presents the projected e-cig use for the overall population of current cigarette 
smokers in the US. The prevalence was found to increase steadily from around 2% in the 
first year to around 6.7% in the eight years. From there onwards, the increase was found to 
slow down and found to be 7.9% at the end of the simulation period.  
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Figure 5. Projected estimate of e-cig prevalence among initial current cigarette smokers 
  
 
 
 
 
Figure 6 presents the projected estimates of e-cig use by age group among current cigarette 
smokers. The highest prevalence at the end of the simulation period was found in smokers 
in the age group of 6-20 years. It was followed closely by smokers in the age group of 21-35 
years. The highest number of e-cig users after those two categories were found to be in 51-
65 years, 36-50 years and lowest in over 65 years.  
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Figure 6. Projected e-cig prevalence by age group among initial current cigarette smokers in the US. 
 
 
 
Figure 7 presents the projected estimates of e-cig use by gender among current cigarette 
smokers. Males and females showed approximately the same prevalence through the 
simulation period. Males were found to be slightly higher users at the end of the simulation 
period.  
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Figure 7. Projected e-cig prevalence by gender among initial current cigarette smokers in the US. 
  
 
 
Figure 8 presents the projected estimates of e-cig use by race among current cigarette 
smokers. Smokers belonging to the white race consistently showed a higher e-cig use than 
smokers belonging to the black and other races. Current smokers belonging to races other 
than black and white showed the lowest prevalence.  
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Figure 8. Projected e-cig prevalence by race among initial current cigarette smokers in the US. 
  
 
 
 
Figure 9 presents the projected estimates of e-cig use by education level race among 
current cigarette smokers. The highest e-cig use was projected in the smokers who had less 
than high school level education compared to smokers with either a high school education 
or a college degree. The prevalence was not very different between the current smokers 
having a high school degree or a college level education. 
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Figure 9. Projected e-cig prevalence by education among initial current cigarette smokers in the US. 
 
E-cig Prevalence in Recent Former Cigarette Smokers 
 
 
 
 
 
 
 
Figure 10 presents the projected e-cig use for the overall population of recent former 
cigarette smokers in the US. Here, the prevalence of e-cig use was found to increase steadily 
from around 2% in the first year to around 7.5% at the end of the simulation period. The 
increased in prevalence was observed to slow down near the end of the simulation period, 
around the 8th year.  
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Figure 10. Projected estimate of e-cig prevalence among initial recent former cigarette smokers 
  
 
 
 
 
Figure 11 presents the projected estimates of e-cig use in recent former smokers classified 
by different age groups. The highest prevalence at the end of the simulation period was 
found in smokers in the age group of 6-20 years. It was followed by smokers in the age 
group of 21-35 years. The prevalence in the age group 36-50 years, and 51-65 years were 
found to be nearly equal at the end of the simulation period. The e-cig use was found to be 
lowest in the age group of >65 years.  
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Figure 11. Projected e-cig prevalence by age group among initial recent former cigarette smokers in the US. 
 
 
 
 
Figure 12 presents the projected estimates of e-cig use by gender among recent former 
cigarette smokers. Unlike the current smokers, the prevalence of e-cig use was projected to 
be higher in females than males. The gap between males and females however reduced as 
the simulation progressed.  
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Figure 12. Projected e-cig prevalence by gender among initial recent former cigarette smokers in the US. 
  
 
 
 
Figure 13 presents the projected estimates of e-cig use by race among recent former 
cigarette smokers. Similar to the projection in current smokers, recent former smokers 
belonging to the white race consistently showed a higher e-cig use than smokers belonging 
to the black and other races. Recent former smokers belonging to the black race showed 
the lowest prevalence.  
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Figure 13. Projected e-cig prevalence by race among initial recent former cigarette smokers in the US. 
  
 
 
Figure 14 presents the projected estimates of e-cig use by different education level among 
recent former cigarette smokers. The highest e-cig use was projected in the smokers who 
had a less than high school education, followed closely by smokers who had a college 
degree, and finally in smokers who had at least a high school education. 
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Figure 14. Projected e-cig prevalence by education among initial recent former cigarette smokers in the US. 
 E-cig Prevalence in Late Former Cigarette Smokers 
 
 
  
 
 
 
 
Figure 15 presents the projected e-cig use for the overall population of late former 
cigarette smokers in the US. Unlike the e-cig prevalence in late former smokers, the 
prevalence of e-cig use in late former smokers was projected to be lower in magnitude. The 
prevalence grew steadily from approximately 0.3% to 1% in first four years, and then 
showed very little increase for the rest of the simulated period. The prevalence was found 
to be 2.9% at the end of the simulation period.   
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Figure 15. Projected estimate of e-cig prevalence among late former cigarette smokers in the US. 
 
 
 
 
 
 
Figure 16 presents the projected estimates of e-cig use in recent former smokers classified 
by different age groups. Among different age groups, the highest prevalence at the end of 
the simulation period was found in smokers in the age groups of 21-35 years. Following 
that, the age groups 36-50 years and 51-65 years showed the next highest number of e-cig 
users. The lowest number of e-cig users were found to be in the age groups of 6-20 years 
and >65 years.  
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Figure 16. Projected e-cig prevalence by age group among initial late former cigarette smokers in the US. 
  
 
 
 
Figure 17 presents the projected estimates of e-cig use by gender among late former 
cigarette smokers. The projected estimates showed that the prevalence was similar in 
males and females through the simulation period. Initially, females had a higher number of 
e-cig users but at the of the simulation period, males showed higher use than females. 
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Figure 17. Projected e-cig prevalence by gender among initial late former cigarette smokers in the US. 
 
 
 
 
Figure 18 presents the projected estimates of e-cig use by race among late former cigarette 
smokers. The majority of e-cig users among late former smokers belonged to the white 
race. Both black and other races projections showed a similar number of e-cig users at the 
end of the simulation period.    
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Figure 18. Projected e-cig prevalence by race among initial late former cigarette smokers in the US. 
  
 
 
 
Figure 19 presents the projected estimates of e-cig use by different education levels among 
late former cigarette smokers. Among late former smokers, the highest e-cig use was 
projected in the smokers who had at least a college level education. Less than high school 
education and high school education had lower number of e-cig users.  
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Figure 19. Projected e-cig prevalence by education among initial late former cigarette smokers in the US. 
E-cig Prevalence in Never Cigarette Smokers 
 
 
 
 
 
 
Figure 20 presents the projected e-cig use for the overall population of never cigarette 
smokers in the US. Similar to the late former smokers, the e-cig prevalence in never 
smokers was projected to be lower in magnitude. The prevalence grew steeply from 0.12% 
to 1.1% in first five years, and then showed an increase to 1.8% at the end of the simulation 
period.  
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Figure 20. Projected estimate of e-cig prevalence among initial never cigarette smokers in the US. 
 
 
 
 
 
Figure 21 presents the projected estimates of e-cig use in never smokers classified by the 
two age groups. The prevalence at the end of the simulation period was found higher 
among never smokers in the age groups of 6-20 years than those in 21-35 years. Both age 
groups showed a steep rise in e-cig use for first 5 years and then showed a steady raise till 
the end of the simulation period.   
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Figure 21. Projected e-cig prevalence by age groups among never cigarette smokers 
 
 
 
 
Figure 22 presents the projected estimates of e-cig use by gender among never cigarette 
smokers. The projected estimates showed that the prevalence was almost similar in males 
and females at the beginning of the simulation period, and at the end of the simulation 
period females were found to be higher users of e-cigs.  
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Figure 22. Projected e-cig prevalence by gender among never cigarette smokers 
 
 
 
 
Figure 23 presents the projected estimates of e-cig use by race among never cigarette 
smokers. Similar to other smoking categories, the majority of e-cig users among never 
smokers belonged to the white race. The projected estimates showed a consistent white 
majority of never smokers who became e-cig users, compared to black and other races 
through the simulation period. Never smokers belonging to other races showed a slightly 
higher number of e-cig users projections compared to black smokers.  
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Figure 23. Projected e-cig prevalence by race among never cigarette smokers 
 
 
 
Figure 24 presents the projected estimates of e-cig use by different education levels among 
never cigarette smokers. The highest number of e-cig users was projected in never smokers 
who had less than high school level education. It was followed by never smokers who had 
at least high school education. Lastly, the lowest number of e-cig users among never 
smokers had a college degree.   
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Figure 24. Projected e-cig prevalence by education level among never cigarette smokers 
 
 
Figure 25. Projected estimate e-cig prevalence in the US population over the simulation period. 
 
Figure 25 presents the projected e-cig use in the model population over the simulation 
period. It was observed that the e-cig use showed a steady growth till the 7th year (15.8%), 
and then showed a decline in the growth from 7th until the 15th year. The e-cig prevalence 
at the end of the simulation period was found to be 19.3%.  
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Figure 26. Comparison of projected e-cig use and conventional cigarette use over the simulation period. 
 
Assuming all the conventional cigarette users transitioned completely to e-cig use without 
any dual use period, we compared the projected e-cig use and the conventional cigarette 
use over the same simulation period (Figure 26). In the conventional cigarette use group, 
the initial population consisted of smokers in the CS, RFS and LFS groups. Each subsequent 
year, the total number of e-cig users at the end of each year from these three groups were 
subtracted from the conventional cigarette group, since we assumed that once a person 
switched to e-cig use, he or she could not go back to using conventional cigarette. The 
conventional cigarette use was found to reduce from 40% to 25% at the end of simulation 
period.  
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Figure 27. Projected e-cig prevalence by age groups in the US population  
 
Figure 27 presents the projected estimates of e-cig use classified by different age groups. 
Among different age groups, the highest prevalence at the end of the simulation period was 
found in people who belonged to the age groups of <21 years and 21-35 years old. It was 
followed by age group 51-65 years and 36-50 years and the lowest number of e-cig users 
were found to be in the age groups of >65 years.  
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Figure 28. Projected e-cig prevalence by gender in the US population 
 
Figure 28 presents the projected estimates of e-cig use by gender. It was observed that in 
the initial stages, e-cig use was more prevalent in females compared to females. However, 
at the end of the simulation period the prevalence was almost similar in males and females, 
approximately 9.5%.  
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Figure 29. Projected e-cig prevalence by race in the US population 
 
Figure 29 presents the projected estimates of e-cig use by race. It was observed that the 
majority of e-cig users belonged to the white race. The projected estimates showed a 
consistent white majority of e-cig users through the simulation period, compared to black 
and other races. Further, people who belonged to the black race showed a higher e-cig use 
than other racial groups.  
 
 
 
 
 
0
1
2
3
4
5
6
7
8
9
10
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
P
er
ce
n
ta
ge
 P
re
va
le
n
ce
Years
White Black Other
 
 
Figure 30. Projected e-cig prevalence by education level in the US population 
 
Figure 30 presents the projected estimates of e-cig use by different education levels. The 
highest number of e-cig users belonged to people with less than high school education. It 
was followed by people who had at least a college degree, and then people who had at least 
high school level education.  
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Sensitivity Analyses 
 
Scenarios 
Prevalence in current smokers (end of 
15 years) 
Reduction in initiating  
risk due to policy 
2% 18.32% 
3% 16.19% 
5% 14.78% 
  
Change in timing of  
policy implementation 
5 years 18.68% 
10 years 21.93% 
No Policy 23.47% 
  
Proportion of people making a quit  
attempt within a year (±15%) 
33% 18.14% 
63% 20.28% 
  
Proportion of people staying quitter  
for that year (±15%) 
14% 18.91% 
4% 19.95% 
 
Prevalence of e-cig use was found to be most sensitive to change in risk associated with 
policies, and time of implementation of the policies. When the risk was increased to 2% 
each year, the prevalence at the end of the simulation period was found to be reduced to 
18.32% from 19.33%.  Increasing it further to 3% and 5% resulted in the reduction of 
prevalence to 16.19% and 14.78%, respectively. Similarly when the time of policy 
application was changed from 7 years to 5 years, prevalence reduced from 19.33% to 
18.68%. When it was changed to 10 years, the prevalence increased to 21.93%. When there 
was no policy application at all, the prevalence was increased to 23.47%. We also evaluated 
Table 10.Prevalence estimates at the end of 15 years for different scenarios in sensitivity analyses in current smokers 
the impact of changing the proportion of people making a quit attempt, and making a 
relapse within the same year. The results of this scenarios did not show a huge impact on 
the prevalence of e-cig use the end of the simulation period. On decreasing and increasing 
the proportion of people making a quit attempt within a year by 15% resulted in a final 
prevalence of 18.14% and 20.28%, respectively. On decreasing and increasing the 
proportion of people staying a quitter for that year after making a quit attempt by 15%, 
resulted in a final prevalence of 18.91% and 19.95%, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Chapter 4 
 
Discussion 
 
 
 
 
 
 
 
 
 
 
 The primary objective of this study was to develop a validated DES model to allow for the 
assessment of e-cig use behavior and prevalence of e-cig in different population groups, 
using data from literature review of several cross-sectional survey and longitudinal e-cig 
studies done on the US population. The simulation replicated the initiating patterns, quit 
attempts and relapses associated with the e-cig use in current, former and never cigarette 
smokers. The model also allowed the change of smoking status between the three smoking 
groups, through the simulation period. We were also able to apply the effect of history by 
including information on prior simulated quit attempts, in addition to individuals’ 
characteristics at the time of each subsequent quit attempt, to make predictions. Further, 
the model gave us an opportunity to investigate the impact of e-cig related policies on the 
prevalence patterns into the future and examining possible real-life patterns of e-cig use.  
 
Our study results showed that e-cig use was projected to be the highest in current cigarette 
smoking population, followed by recent former smokers, late former smokers and lowest in 
never smokers. The projected estimate after the first year of simulation in current smokers 
was found to be around 2.1%. This finding was found to be consistent with the results of a 
survey conducted by CDC which reported the prevalence of regular e-cig use to be around 
1.9% (King et al., 2013). It provides initial evidence to support the model validity and its 
potential to obtain accurate estimates with adequate data availability. The overall 
projected e-cig use for the population of current cigarette smokers in the US was found to 
increase to 6.7% in eight years, and then to 7.9% at the end of the simulation period. The 
slow growth rate after 8 years could be attributed to the launch of the e-cig control policy, 
which was implemented at the 7th year, and which resulted in lowering risk of initiation of 
e-cig each subsequent year. Next, the prevalence of e-cig use in recent former smokers was 
found to be less than current smokers, but still considerably higher than late former and 
never smokers. The e-cig use pattern followed the same trajectory as in current smokers, 
indicating the behavior of recent former and current smokers towards the use of e-cig is 
not very different. In late former smokers and never smokers, the e-cig use was projected 
to be lower than current and recent former smokers. This was consistent in current trend 
in the use of e-cig, where the only never smokers who become regular e-cig users are 
relatively young adults and teenagers, resulting in a low overall population prevalence 
(Camenga et al., 2014).   
 
Differences in the use of e-cigarettes were observed across subpopulations. Specifically, 
younger age groups, whites, females and smokers having less than high school education 
were found to be highest users of the e-cig among current, recent former, and never 
smokers. Higher use among younger adults may be related to the fact that e-cigarettes are 
traditionally marketed through electronic and social media (Noel, Rees, & Connolly, 2011; 
Yamin, Bitton, & Bates, 2010). Also, the higher prevalence of use among current smokers 
could be related to the marketing of e-cigarettes as smoking cessation aids (Adkison et al., 
2013; Etter & Bullen, 2014).  
 
Our research provides context to identify future population-based changes related to e-cig 
use and guide the design of a more informative longitudinal research. National data on e-
cig use by middle and high school students gathered via the National Youth Tobacco Survey 
in 2011 and 2012 reported that among middle and high school students, ever-use of e-
cigarettes (tried at least once) increased from 3.3% to 6.8%, whereas current use (within 
the last 30 days) increased from 1.1% to 2.1% (Agaku et al., 2014). That data was correctly 
estimated by our model as observed by the results of the 1st year simulation. Another 
analysis of National Youth Tobacco Survey data from the same time period confirmed that 
current e-cigarette users were much more likely to be current cigarette smokers, which 
was consistent with our findings (Bunnell et al., 2015).  
 
Our study is also a first in modeling the impact of future policies regulating e-cigs at 
different times.  Because e-cig is a new product, lack of scientific evidence has been a key 
factor for the absence of federal regulations. Our study provides an opportunity to examine 
the potential impact of future policies on e-cigs use by modeling risk reduction each 
subsequent year after implementation of a policy. Another advantage of our study was that 
we were able to show the impact of varying the policy effect, specifically the magnitude of 
risk and the time at which the policy will be implemented, in our sensitivity analyses.  
 
Our model also enables meaningful analyses of outcomes in population subgroups. For 
instance, the prevalence of e-cig use among younger age group and white people could be 
more comprehensively captured. By accounting for subject characteristics when predicting 
e-cig use, relapse, and quit attempts, this model provides a powerful tool to evaluate the 
usefulness of e-cigs for improving quit rates, and reducing the risk of relapse among 
different subgroups of the population. 
 
  
With the current ongoing research on the health effects related to the use e-cigs, this model 
could be used to predict vaping-related disease and health utilities once the data becomes 
available. Although the exact information on diseases attributed to e-cig use is not be 
expected to come out in near future, but the effects on proxy measures, such as 
physiological biomarkers, will be able to provide some insight in the risks related to the use 
of e-cigs.  
 
We have to be mindful of the fact that a large proportion of current e-cig users are 
concurrently using conventional cigarettes (Brandon et al., 2015). Since we did not have 
access to longitudinal individual level data, we were not able to model the time dependent 
aspects of e-cig behavior such as time to first quit attempt, time to relapse, time spent by a 
smoker in transitioning from cigarette to e-cig. This information when available, could be 
used by the investigators to predict the time-dependent aspects listed above to estimate 
important outcomes such as duration of time where the current cigarette smoker is using 
both product (dual use), or time taken to completely switch to e-cig.  
 
The main strength of this model is that it was able to incorporate significant predictors of 
e-cig initiation obtained from the literature and show their cumulative effect in making the 
individuals use or not use an e-cig. Thus, this model structure could provide a solid 
foundation from which a flexible, lifetime e-cig use behavior model can be developed that 
can accommodate multiple quit attempts, relapse, transitioning between current, former 
and never users over time in diverse populations.  
  
The main impediment to developing a lifetime DES is the difficulty in obtaining accurate 
and reliable data on long term patterns of quit attempts. Data that would allow for accurate 
individualized predictions on sequences of smoking behavior, intervals between quit 
attempts and long-term relapse rates, are required to fully harness the potential of the 
modelling technique. Nevertheless, even in the absence of these data, a lifetime DES built 
on the current model would allow for informative exploratory analyses that are grounded 
in reliable individualized predictions and patterns. Based on our literature review, we 
believe that the data is currently being collected and will be released sometime in near 
future. Once the data is available, capturing the time-dependent relationships will add 
tremendous value to a lifetime model.   
 
We believe that the data related to e-cig attributed mortality will not become available in 
near future. Hence, it will not be possible to model the mortality rates related to e-cig use. 
However, it is certainly possible to use the rates of smoking-related disease attributed to e-
cig use, compare them with disease rates attributed to conventional cigarette smoking and 
other tobacco products, and predict mortality after applying appropriate assumptions.  
 
In future, additional validation of the model predictions would also increase confidence in 
the reliability of the current predictive equations. The structural validation and the 
comparison of the results against the data sources indicated that the simulation predicted 
the short term prevalence estimates close to the real values, and performed well when 
implemented in key population subgroups. However, validation exercises performed 
against sources different than those used in developing the core equations would be 
valuable.  
 
Data on e-cig use by youth and adults have been gathered primarily from Web-based 
surveys and convenience sampling, including regional samples, and from participants in 
online e-cigarette forums. Interpreting such data is difficult, and it is necessary that data 
collected at the individual level is released publicly, to foster research on different areas of 
interests related to e-cigs. Furthermore, most of the cross sectional or survey research 
published till date use has evaluated just the short term use of e-cig use, mostly for 1 or 2 
years. Similarly, the clinical trials studies conducted on e-cig use have also followed the e-
cig users for the duration of 6 months or 12 months. Our model used that information, 
incorporated into our model, followed the e-cig users for 15 years, and tried to project the 
behavior pattern and the use trajectory of e-cigs.  
 
Some studies observed that e-cigs may contribute to prevent relapse in former smokers 
and to promote smoking cessation in current smokers, which essentially means getting 
them off from conventional cigarettes (Biener & Hargraves, 2015; McMillen et al., 2014). It 
would have been a significant outcome to look at in our model as well however, the 
evidence is still scarce according to our review of the published literature. 
 
 
 
 We made a strong assumption in our study that all e-cigs contained nicotine. The recent 
policy statement on e-cigs from the American Association for Cancer Research reported 
that currently there are around 7000 unique flavored e-cigs on the market (Brandon et al., 
2015). The report suggested that flavored tobacco is particularly appealing to youth, and 
some flavored combustible products potentiate continued use and addiction. There is a 
concern that flavored e-cigs may have a similar effect on the youth, however there is no 
available studies which have accessed flavors in general (Brandon et al., 2015). In future, 
our model can be used when the data on flavors becomes available, to estimate the impact 
of different flavors on the pattern of e-cig use among the young users. 
 
The use of e-cigs by never smokers would present a public health concern, but this is a 
particular concern with respect to youth, especially if e-cigs serve as a pathway to other 
tobacco products, including combustible cigarettes (Grana, 2013). In our study, we were 
limited by the data availability and could only estimate the transition of never smokers to 
e-cigs but could not model their transition to the use of regular tobacco products. However 
in near future, with the availability of adequate data, we could show transition of never 
smokers from e-cigs to other tobacco products can be a significant application of this 
model.  
 
Population benefit or harm depends largely on public’s perception of the products and 
their patterns of use. The risk may increase if dual use with other tobacco products is 
prevalent, or cessation is deterred by persons using e-cigs to circumvent smoke-free laws. 
Studies conducted with e-cigarette users, demonstrated that they perceive the products to 
be less toxic than conventional cigarettes and have used them as a smoking cessation 
device or to avoid exposing others to tobacco smoke (Brown et al., 2014; Pearson et al., 
2012). However, the research on their efficacy for smoking cessation is still ongoing and 
most of the published studies reported a small sample size making their studies 
underpowered. Further research on the rates and health effects of dual use is critical for 
assessing and considering total public health impact of e-cigs. Future studies should try to 
assess the dose–response relationship for certain biomarkers of cardiovascular effects or 
lung cancer effects with the use of e-cigs.  
 
The evidence regarding the risks and benefits of e-cigs in different segments of the 
population such as current smokers and never smokers is difficult to interpret, because the 
market place of e-cigs products is evolving rapidly. Research in this field is complicated by 
the ever-changing and wide variability among and within different e-cig products, a lack of 
standardized definitions of e-cigs, variable user terminology, and a lack of established 
protocols for conducting e-cig research, including clinical trials (Brandon et al., 2015). 
However, despite these challenges, research on e-cigs is on the right track and progressing 
rapidly. The NIH and the FDA are providing recommendations for studying these products, 
including different population sub groups such as healthy volunteers as well as vulnerable 
populations, such as people suffering from cancer and those with other acute or chronic 
medical conditions. More research is needed to understand how different design features 
relate to dependence and toxicity, including if the compounds in e-cigs react chemically and 
if these compounds are absorbed into the bloodstream. Research is also needed to 
understand the effect e-cig use, including second- and third hand exposure to population as 
well. Studies should also examine the efficacy and safety of e-cigs in patients with cancer 
treated with surgery, chemotherapy, and radiotherapy and potential interactions with 
these therapies. Among smokers, long term controlled clinical trials are needed to 
determine whether e-cigs facilitate or hinder short- and long-term smoking cessation as 
well as whether it increases nicotine dependence. Studies should consider also outcomes 
related to health conditions such as cardiovascular diseases, COPD, lung cancer and stroke. 
These conditions have an established history with conventional cigarette smoking.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Limitations 
 
The biggest limitation of this study was the use of self-reported values of e-cig use based on 
age, gender, race and education status. Due to the absence of standardized recorded 
individual level data, we were unable to obtain the mutually exclusive prediction 
probabilities. However, we used appropriate mathematical rules to get a correct estimate 
of the probabilities associated with the e-cig use. The model also relied on a number of data 
sources, including surveys and longitudinal e-cig studies done on the different populations, 
which may be responsible for variation in the results across different groups. Another 
limitation was not able to differentiate people who make a quit attempt and relapse, and 
those who do not relapse. We did allow a definite proportion of people to pass through, but 
that proportion was directly utilized from a survey without the knowledge of individual 
characteristics of people making or not making the quit attempt or relapse (Kasza et al., 
2014). Next important limitation was that we could not validate our model projections 
against real world data. Because e-cig is a relatively new product, long term longitudinal 
studies will be required to compare and validate the results of our model. Additionally, 
time to quit attempt, time to relapse, and time to transition from regular cigarette to e-cig 
was not modelled because of lack of time dependent data. Because the smokers were 
generated and assigned attributes based on the NHIS data, simulated patients may not 
accurately represent real-world patients, which could limit generalizability to real-world 
settings. In addition, we assumed everyone to be undergoing the changes and going 
through different states as defined by the path of the model. This does not happen in the 
real world, where the movement of people is more dynamic and random.  
  
 
 
 
 
 
 
 
 
Chapter 5 
 
Conclusion 
 
 
 
 
 
 
 
 
The benefits and harms of e-cig use must be evaluated with respect to the population as a 
whole and take into account the effect on youth, adults, never smokers, former smokers 
and current smokers. There are currently too few data on the behavior pattern of e-cigs 
and their efficacy as cessation products to recommend their use for the general population. 
Our study evaluates the long term use pattern of e-cigs in the US population. We mainly 
estimated the prevalence of e-cigs in current, former and never smokers for the period of 
15 years, using the current data. Our population model will help predict changes in 
individual behaviors and patterns associated with the use of e-cigs. It will also help to 
address the problem of scarce data resources related to e-cig use and provide guidance for 
conducting more research on generating real world evidence to look into more relevant 
outcomes. It will also encourage policymakers to review the rapidly changing pattern of e-
cig use and make public health decisions by using our future projection of e-cig use.  
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Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
Table 11. Model Population descriptive results: 
 Current smokers 
(N= 12665)  
 
Former smokers 
(N= 15226)  
  
 
Never smokers 
(N=40801) 
Age (%)         
<21 years 
21-35 years 
36-50 years 
51-65 years 
>65 years 
 
1.825 
34.701 
33.901 
23.760 
5.811 
 
0.511 
13.602 
18.954 
31.671 
35.272 
 
2.771 
29.484 
30.732 
22.859 
14.151 
Gender 
Male 
Female 
 
55.554 
44.445 
 
52.453 
47.556 
 
42.115 
57.884 
Race 
       White 
       Black 
       Other 
 
68.279 
13.949 
17.771 
 
80.394 
8.061 
11.552 
 
66.37 
12.228 
24.534 
Education status 
Less than high school  
High school diploma 
 
 Any college 
 
9.615 
43.781 
46.603 
 
 
11.598 
37.813 
50.589 
 
63.237 
12.228 
24.534 
CPD (Means, SD) 11.87, 8.80 ------------- -------------- 
Years of regular smoking 
(Means, SD) 
27.02, 15.69   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
At least 1 quit attempt in 
past 12 months 
46.97  
 
--------------- -------------- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 12. Simulated population for each year after applying the birth and death rates 
 
Simulated population for 5 years  
Years   + Birth rate -Death rate 
Total 
population 
1 
Initial N= 
100000.00 0.00 0.00 100000.00 
2 100000.00 101330.00 100478.83 100478.83 
3 100478.83 101815.20 100959.95 100959.95 
4 100959.95 102302.72 101443.37 101443.37 
5 101443.37 102792.57 101929.11 101929.11 
6 101929.11 103284.77 102417.18 102417.18 
7 102417.18 103779.33 102907.58 102907.58 
8 102907.58 104276.25 103400.33 103400.33 
9 103400.33 104775.55 103895.44 103895.44 
10 103895.44 105277.25 104392.92 104392.92 
11 104392.92 105781.35 104892.78 104892.78 
12 104892.78 106287.86 105395.04 105395.04 
13 105395.04 106796.79 105899.70 105899.70 
14 105899.70 107308.17 106406.78 106406.78 
15 106406.78 107821.99 106916.28 106916.28 
Prevalence estimates for each year 
Years 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Overall 
Percent 
Prevalence 2.0952 3.1025 3.9464 4.5391 5.1388 5.8339 6.1518 6.6226 6.9427 7.2835 7.3419 7.5792 7.6215 7.6802 7.7148 
Standard 
errors 
 
0.852 
 
0.767 
 
0.813 
0.675 0.684 0.774 0.868 
 
0.796 
0.873 
 
0.782 0.654 0.861 0.882 0.768 0.685 
Age                     
 
    
6-20 years 0.5826 0.9695 1.2824 1.4517 1.6182 1.8133 2.0445 2.0865 2.1158 2.2344 2.2705 2.2953 2.3284 2.3164 2.3941 
21-35 years 0.5381 0.7115 0.9218 1.2703 1.4681 1.5212 1.6367 1.7366 1.9511 2.0468 2.1718 2.2674 2.2931 2.3075 2.3413 
36-50 years 0.1794 0.2285 0.4001 0.6269 0.8405 0.9502 1.0414 1.0508 1.0843 1.0229 1.0643 1.0834 1.1648 1.1592 1.1692 
51-65 years 0.5939 0.6424 0.9912 1.2189 1.3881 1.4943 1.5048 1.6676 1.6991 1.8369 1.7642 1.7149 1.7298 1.7643 1.7985 
>65 years 0.2012 0.2112 0.2088 0.1888 0.1315 0.1244 0.1561 0.1625 0.1225 0.0625 0.0682 0.0546 0.0513 0.0496 0.0482 
                      
 
    
Gender 
                    
 
    
Male  0.9312 1.4244 1.8615 2.1164 2.5347 2.8361 2.9832 3.3398 3.6464 3.7331 3.7251 3.8563 3.8426 3.9321 3.9167 
Female 1.1643 1.6687 2.0437 2.3802 2.6918 2.9239 3.1748 3.2937 3.4235 3.5525 3.6278 3.7231 3.7825 3.7514 3.8024 
                      
 
    
Race 
                    
 
    
White 1.0985 1.4027 1.8233 2.1594 2.3637 2.5579 2.7679 2.9042 3.0492 3.1856 3.2041 3.2984 3.3231 3.3649 3.4025 
Black 0.8543 1.1145 1.4529 1.7638 1.9286 2.1242 2.2404 2.4497 2.5234 2.6493 2.6643 2.7673 2.7965 2.8052 2.8543 
Other 0.3424 0.5619 0.6588 0.8034 0.8408 1.1254 1.1335 1.3289 1.3856 1.4675 1.5124 1.5243 1.5671 1.5241 1.5934 
                      
 
    
Education 
level 
                     
    
Less than high 
school 
0.8367 1.4694 1.7032 1.9367 2.2411 2.4358 2.5636 2.7027 2.8613 2.9152 3.0734 3.1243 3.1906 3.2834 3.3127 
 
Table 13. Projected e-cig prevalence for each year in the simulation period within different demographic categories of current cigarette smokers.
High school 0.5985 0.8163 1.0102 1.1423 1.3365 1.5272 1.6598 1.7668 1.8379 1.9316 1.8854 1.9465 1.8437 1.8671 1.8207 
College 0.66 1.0174 1.2418 1.4666 1.5612 1.8809 1.9484 2.1643 2.2134 2.3123 2.3965 2.5119 2.5974 2.6074 2.6846 
Prevalence estimates for each year 
Years 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Overall 
Percent 
Prevalence 2.0444 3.5079 4.4298 5.2325 5.7254 6.1126 6.6843 7.1021 7.2324 7.3062 7.3483 7.3841 7.4267 7.4608 7.5117 
Standard 
errors 
 
0.852 
 
0.767 
 
0.813 
 
0.675 
 
0.684 
 
0.774 
0.868 
 
0.796 
0.873 
 
0.782 0.654 0.861 0.882 0.768 0.685 
Age                     
 
    
6-20 years 0.8584 1.4431 1.8023 2.1168 2.2941 2.4029 2.4967 2.5069 2.5993 2.6026 2.6037 2.6041 2.6571 2.6519 2.6934 
21-35 years 0.5852 0.9058 1.1331 1.3213 1.4415 1.6039 1.8146 2.0217 2.1132 2.2102 2.2167 2.2583 2.3119 2.3508 2.3781 
36-50 years 0.3803 0.6961 0.9849 1.0673 1.1589 1.2704 1.3198 1.4625 1.4492 1.4951 1.4803 1.4545 1.4237 1.4209 1.4068 
51-65 years 0.117 0.3275 0.4829 0.6125 0.8047 0.9754 1.0975 1.1189 1.1136 1.0239 1.0228 1.0193 1.0346 1.0285 1.0274 
>65 years 0.06963 0.0718 0.0926 0.1006 0.09872 0.09312 0.0857 0.0755 0.0729 0.0615 0.0601 0.0583 0.0549 0.0486 0.0431 
                      
 
    
Gender 
                    
 
    
Male  0.8199 1.5683 2.0191 2.3315 2.4435 2.8098 3.1144 3.4887 3.4852 3.5228 3.5579 3.5816 3.5894 3.5926 3.6051 
Female 1.2267 1.9456 2.4148 2.9014 3.2851 3.3178 3.5714 3.6124 3.7479 3.7845 3.7901 3.8002 3.8373 3.8719 3.9047 
                      
 
    
Race 
                    
 
    
White 1.0949 1.7359 2.1449 2.7073 2.9332 3.2344 3.4121 3.5218 3.6012 3.6424 3.6593 3.6804 3.6979 3.7014 3.7107 
Black 0.4163 0.9577 1.0825 1.1132 1.2802 1.3151 1.4754 1.6535 1.5981 1.5972 1.6043 1.5941 1.5538 1.5406 1.5912 
Other 0.5356 0.8247 1.2085 1.4122 1.5161 1.7275 1.8078 1.9358 2.0314 2.1574 2.1701 2.2045 2.2179 2.2282 2.2196 
                      
 
    
Education 
level 
                     
    
Less than high 
school 0.6832 1.2108 1.6356 1.9082 2.1088 2.2772 2.4736 2.6997 2.7104 2.7829 2.7902 2.8007 2.8517 2.8861 2.8942 
High school 0.4737 0.8826 1.0617 1.2959 1.4042 1.5114 1.7323 1.8052 1.9421 1.9602 1.9054 1.9342 1.9865 1.9907 1.9145 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
College 0.8748 1.4085 1.7325 2.0284 2.2124 2.3244 2.4676 2.5215 2.584 2.6163 2.6304 2.6584 2.6841 2.689 2.7123 
Table 14. Projected e-cig prevalence for each year in the simulation period within different demographic categories of recent former cigarette smokers. 
 
 
 
Prevalence estimates for each year 
Years 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Overall 
Percent 
Prevalence 0.2968 0.6148 0.8914 1.1746 1.3793 1.5313 1.6759 1.7946 1.9372 2.0112 2.1409 2.1764 2.2034 2.2374 2.2946 
Standard 
errors 
0.152  
  
0.167 
  
0.183 
0.175  
  
0.184 
  
0.174 
  
0.168 
  
0.196 
  
0.173 
0.182  
0.154 0.181 0.182 0.168 0.185 
Age                     
 
    
6-20 years 0.1433 0.1763 0.1856 0.1942 0.2243 0.2772 0.2868 0.3126 0.3243 0.3346 0.3371 0.3458 0.3549 0.3824 0.3945 
21-35 years 0.1239 0.2061 0.2409 0.2967 0.3909 0.4874 0.5224 0.5903 0.6493 0.7824 0.8106 0.8347 0.8643 0.8943 0.8973 
36-50 years 0.05784 0.1084 0.1423 0.1698 0.2691 0.3029 0.3407 0.3941 0.4172 0.438 0.4672 0.4827 0.5042 0.5247 0.5382 
51-65 years 0.0685 0.1258 0.1931 0.2413 0.2915 0.3342 0.3616 0.4022 0.4391 0.4482 0.4691 0.4782 0.4893 0.5092 0.5247 
>65 years 0.00317 0.0179 0.0318 0.0259 0.0357 0.0414 0.04176 0.04123 0.0409 0.04124 0.0462 0.0497 0.0582 0.0416 0.0472 
                      
 
    
Gender 
                    
 
    
Male  0.1415 0.2853 0.4312 0.5291 0.6407 0.7734 0.8125 0.9042 0.9313 1.0942 1.258 1.211 1.218 1.241 1.2954 
Female 0.1541 0.2951 0.4673 0.6413 0.6683 0.7667 0.8534 0.8946 0.9067 0.9184 0.9361 0.9643 0.9833 0.9892 1.0028 
                      
 
    
Race 
                    
 
    
White 0.1953 0.2774 0.3986 0.4928 0.6147 0.6913 0.7105 0.7831 0.8182 0.9395 1.0523 1.0612 1.1085 1.1191 1.1574 
Black 0.0215 0.1442 0.2326 0.3201 0.3731 0.3966 0.4091 0.4127 0.4813 0.4977 0.5413 0.5543 0.5691 0.5724 0.5746 
Other 0.0795 0.2085 0.2774 0.3695 0.4313 0.4839 0.5084 0.5225 0.5876 0.6187 0.6431 0.6582 0.6307 0.6479 0.6852 
                      
 
    
Education 
level 
                     
    
Less than high 
school 
0.1292 0.1249 0.2076 0.2774 0.2905 0.3141 0.3571 0.4085 0.4162 0.4471 0.4682 0.4709 0.4829 0.4936 0.5014 
High school 0.0773 0.1701 0.2331 0.3254 0.3803 0.4062 0.4851 0.5014 0.5273 0.5523 0.5973 0.6073 0.6243 0.6429 0.6824 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
College 0.0903 0.2049 0.4612 0.5847 0.6324 0.7642 0.8486 0.8813 0.8936 1.0174 1.0985 1.1085 1.0972 1.1023 1.1102 
Table 15. Projected e-cig prevalence for each year in the simulation period within different demographic categories of late former cigarette smokers. 
 
 
 
 
 Prevalence estimates for each year 
Years 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Overall Percent 
Prevalence 0.1239 0.5103 0.6944 1.0115 1.1284 1.3058 1.3778 1.4019 1.4835 1.5086 1.5619 1.6731 1.7116 1.7513 1.8092 
Standard 
errors 
0.152  
  
0.167 
  
0.183 
0.175  
  
0.184 
  
0.174 
  
0.168 
  
0.196 
  
0.173 
0.182  
0.154 0.181 0.182 0.168 0.185 
Age                     
 
    
6-20 years 0.0749 0.3329 0.4286 0.6572 0.7224 0.7975 0.8089 0.8241 0.8537 0.8729 0.8763 0.914 0.9557 0.9605 0.9856 
21-35 years 0.049 0.1774 0.2658 0.3543 0.4654 0.5142 0.5772 0.5878 0.6347 0.6392 0.6842 0.7598 0.7545 0.7981 0.8152 
                      
 
    
Gender 
                    
 
    
Male  0.0453 0.2216 0.3227 0.4398 0.5021 0.6297 0.6765 0.6816 0.7181 0.7278 0.7515 0.7841 0.8071 0.8234 0.8372 
Female 0.0717 0.2974 0.3717 0.5728 0.6263 0.6736 0.7008 0.7203 0.7695 0.7813 0.8173 0.8864 0.9054 0.9276 0.9634 
                      
 
    
Race 
                    
 
    
White 0.0616 0.2274 0.2894 0.3991 0.4372 0.5106 0.5617 0.5832 0.5993 0.6076 0.6143 0.6928 0.7014 0.7153 0.7386 
Black 0.0175 0.1104 0.1912 0.2857 0.3111 0.3735 0.3733 0.3717 0.4169 0.4247 0.4562 0.4734 0.4871 0.4985 0.5221 
Other 0.0379 0.1635 0.2238 0.3467 0.3756 0.4212 0.4428 0.4561 0.4873 0.4862 0.4913 0.5138 0.5243 0.5382 0.5472 
                      
 
    
Education 
level 
                    
 
    
Less than high 
school 0.0667 0.2259 0.3171 0.4511 0.5161 0.6135 0.6449 0.6571 0.6738 0.6917 0.7114 0.7643 0.7841 0.7937 0.7925 
High school 0.0416 0.1845 0.2267 0.3252 0.3583 0.3835 0.4051 0.4224 0.4307 0.4415 0.4521 0.4721 0.4876 0.4908 0.4921 
College 0.0087 0.1175 0.1606 0.2452 0.2638 0.3148 0.3236 0.3251 0.3801 0.3748 0.4072 0.4362 0.4472 0.4421 0.4529 
Table 16. Projected e-cig prevalence for each year in the simulation period within different demographic categories of never cigarette smokers. 
 
 
 Using Arena 
 
The Arena modeling environment can be started from the Start menu and navigated to 
Programs > Rockwell Software > Arena. The Arena modeling environment will open with a 
new model window 
 
 
 
 
 
 
 
To model the process in Arena, we work in three main regions of the application window. 
The Project Bar hosts panels with the primary types of objects that we work with: The 
basic Process panel contains the modeling shapes, called modules that are used to define 
the process. Reports panel contained the reports that are available for displaying results of 
simulation runs. Navigate panel allows to display different views of the model, including 
navigating through hierarchical sub-models and displaying a model thumbnail. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Building the model in Arena 
 
1) Creating the smokers 
 
First part consisted of generating 100,000 smokers and assigning an exponential 
distribution to their time of arrival. 
 
 
 
 
 
 
 
 
 
  
 
 
2) Sending the smokers into one of the four smoking groups 
 
Next, based on the NHIS distribution of CS, RFS, LFS and NS, the generated smokers 
were sent into one of the 4 branches. 
 
 
3) Assigning the baseline characteristics  
 
Next step was to assign the baseline characteristics to the smokers based on the NHIS 
estimates, and assigning corresponding probability distributions. Following figure 
shows the assignment of baseline characteristics and smoking related characterstics to 
CS. Similar assignments were done to RFS, LFS and NS.   
 
  
 
 
 
 
 
 
 4) Assigning history 
Next step in CS was to assign history of quit attempts to the generated population of 
current smokers. The quit attempts history were assigned in a way that any new 
attempt made inside the simulation model will  be added on to the previous quite 
attempts incorporated in the history. 
 
 
 
 
 
 
 
 
  
5) Risk assignment 
The following figure shows how to assign the risk/mutually unexclusive probabilities 
based on the baseline and smoking related attributes.   
 
 
 
The following figure shows the assignment of risks related to different levels of age 
groups, by indexing the risks in 5 different rows corresponding to 5 different age 
groups. 
  
6) Decide the initiation of e-cig  
This was decided by applying the probability equations discussed in the methods 
section. The equation was inserted to percent true module as shown in the figure below. 
 
 
 
 7) Quit attempt and relapse within one year  
This was done by allowing 48% of smokers to pass through the true branch and rest 
52% to pass through the false branch. Within those 48%, 9% were allowed to pass 
through without making a relapse. Rest of them made a relapse and went into the loop 
again. 
 
 
 
  
8) Increase in risk of initiation with every relapse 
The risk of initiating an e-cig in the next year increased with every quit attempt made in 
the simulation. This was assigned as shown below. 
 
 
 
9) Recording prevalence 
People who made a relapse and who were continuing to use e-cig were recorded as e-
cig users, and were recorded as regular e-cig user.  
 
 
10) Waiting for another year 
After the end of 1 year, smokers were allowed to wait for one year and assigned a new 
age.  
 
  
 
 
 
 
 
 
 
11) Modeling the effect of policy 
The policy effect was modelled by assigning an overall risk which reduced by 1% each 
year, a person decided to wait to initiate the e-cig.  
  
 
 
  
 
 
 
 
12) Setting up the simulation 
Finally, the run is set up by filling up the details in the run setup window. The model 
was made to run 100 replications for each group for each cycle. The vales can be 
changed by the users as per the objectives. The model clock and initial date could be 
assigned as shown below. 
 
 
 
 
 
  
 
 
 
 
 
 
